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Chapter 1
Introduction
1.1 Demand of Novel Diagnostics and Therapeutics
Many diseases are diagnosed at an advanced stage leading to poor prognosis for the
patients emphasising the requirement for new diagnostic tools for early and efficient
diagnosis. This aim can be reached by analysis of samples on the genomic and pro-
teomic level. A further new challenge for diagnostics and therapeutics is to reach a
state called personalised medicine. Complex genetic and proteomic alterations lead
to diseases like cancer which are individual for each patient. These alterations are
impossible to measure by traditional pathological methods (WULFKUHLE et al., 2004).
Detailed molecular classification of individual tumours provide the opportunity for
clinicians to choose for each patient the best therapy (L IOTTA and PETRICOIN, 2000).
There has been an extensive effort to sequence the human genome, resulting in
the identification of ten thousands of new genes. This knowledge is the basis for one
of the first steps on the way to individualise therapeutics: the large-scale analysis of
gene expression using DNA arrays (LIANG and PARDEE, 2003). Actually, up to 30,000
olignucleotides or cDNA can be accommodated on arrays (WULFKUHLE et al., 2004).
Pattern recognition software allows the identification of gene clusters and genes whose
expression behaves in a similiar way. Therefore DNA microarrays can be applied to
the analysis and classification of cancer tissues. Studies were performed that showed
that expression profiles can provide information for the prediction of tumour classes
and clinical outcomes of disease, e.g. in case of leukamia and lymphomas (GOLUB et
al., 1999). GOLUB et al. reported the identification of 50 genes, whose analysis provide
the opportunity to distinguish between acute myelogneous leukaemia and acute lym-
phocytic leukaemia. This group was followed by others who used expression profiling
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for the classification of tumours. But gene expression can also have a positive impact
on the therapeutic descisions. VAN’T VEER et al. (2002) identified a gene expression
signature by DNA microarray analysis on primary breast tumours. This signature is
predictive of a short interval to distant metastases. They found out that 70-80% of
women receiving chemotherapy to reduce the risk of metastases would not develop
metastases without treatment. These patients suffer the numerous side-effects without
benefit. Expression profiling also led to the identification of targets for therapy, such as
ErbB2, overexpressed on selected breast cancers and therefore led to the development
of therapeutic agents targeting these molecules (WULFKUHLE et al., 2004).
But although this discipline delivers masses of new and important information
leading to new approaches in diagnosis and therapy of diseases, it becomes clear that
the information concerning the gene expression does not bring light into the com-
plex network of cellular processes and interaction networks. Genomic data deliver
only little information regarding modifications, interactions, activities, and, ultimately,
the function of proteins. Beside this there is a lack of information concerning the
abundance of proteins, due to the missing correlation between gene activity and pro-
tein abundance (GYGU et al., 1999; ANDERSON and SEILHAMER, 1997). In addition,
the 25,000 to 30,000 human genes give rise to probably more than a million proteins
(VENTER et al., 2001; BAAK et al., 2003). However posttranslational modifications can
be of particular importance for the healthy state of a cell. Transcript levels may be
the same in a malignant sample and a non malignant sample for a certain protein, but
a stronger phosphorylation or ubiquitinylation can lead to a dramatically increased or
decreased activity (WILKINSON, 1995; COHEN, 2000; ATTAIX et al., 2001). Furthermore,
the biochemical processes underlying a disease can only be understood completely if
protein/protein interactions are analysed on a whole cell basis (ZHU et al., 2001) using
living cells.
Two-dimensional-gel electrophoresis (2DE) and mass spectrometry (MS) are the
most popular approaches for the description of the proteome (GLOECKLER and AN-
GENENDT, 2003). This technique underwent several improvements in form of immo-
bilised pH-gradients leading to higher reproducibility and resolution (W ILDGRUBER
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et al., 2000) since its invention in 1975 (KLOSE, 1975; O’FARRELL, 1975). This en-
ables the separation of protein isoforms that differ by post-translational modifications
(GLOECKLER and ANGENENDT, 2003). Despite these achievements there are still lim-
itations and problems regarding automatisation and reproducibility. While spot ex-
cision can be done by automatic spot pickers, the gels have to be applied and run
manually. Thus, it is a very time consuming and expensive technology. Hydrophobic
proteins as well as high molecular protein are difficult to separate (WEHR, 2003).
The proteins are commonly identified by mass spectrometry subsequent to tryptic
digest. Until 1988 mass spectrometry (MS) was used for the identification of volatile
compounds. This technique could not be applied to proteins, because these large and
charged molecules could not be transferred to the vacuum. In 1988, the matrix-assisted
laser desorption and ionisation was developed, which enables the transfer of pro-
teins into the gas-phase and therefore allowed the identification of proteins (KARAS
and HILLENKAMP, 1988). Although this technology provides the possibility of high
throughput applications, it still requires a large database and computer facilities for
the identification of the analysed peptides.
Using the classical approaches such as 2DE and MS for the analysis of the pro-
teome the proteins are measured independently. But there is a development towards
functional proteomics, where the cellular network should be described. To meet these
requirements, high throughput technologies have to be developed for the dissection of
protein interactions. Furthermore the trend develops towards the use of combinations
of several different markers in parallel. Single markers often do not meet the require-
ments of sensitivity and specificity. The most promising tool is the protein and anti-
bodymicroarray (GLOECKLER and ANGENENDT, 2003). DNAmicroarray have already
proven in 1996 the suitability of this approach in health research (DERISI et al., 1996).
In case of protein microarrays proteins are spotted onto matrices, e.g. glass or mem-
branes, enabling the analyses of protein-protein interactions, expression patterns, post-
translational modifications or protein drug interactions, allowing the parallel analysis
of large numbers of proteins at a time (HAAB et al., 2001). Different chip formats have
been investigated and they can be classified in a number of ways, according to the na-
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ture and complexity of the spotted proteins, the surface chemistry, the composition of
the analyte and how signals are generated and detected (GLOEKLER and ANGENENDT,
2003). However protocols for the immobilisation of the proteins to the arrays have to
be optimised ensuring the functionality of the binding site of the protein.
The biggest part in the field of analytical protein chips belongs to antibody based
chip formats. Antibodies are naturally the molecules of choice for most affinity based
applications as they are molecules with a very broad range of specificity, allowing the
generation and identification of several individual antibodies against a single protein.
Thus, antibodies binding to different epitopes of the same target as well as exhibiting
different degrees of affinity and binding strength can be identified. On the other hand,
antibodies are molecules with a very high degree of structural conservation – as mani-
fested in their generally similar backbone. This conservation allows the development
of systematized and industrialized processes as well as a variety of possible immo-
bilisation methods. Microarrays of antibodies allow detection and quantification of
1 ng/ml, corresponding to an absolute detection limit of 20 pg/20 µl sample (HAAB et
al., 2001), which favours the detection method instead of 2DE with detection limits of
1-5 ng/protein (ROEGENER et al., 2003; CANDIANO et al., 2004).
There are different areas of applications for protein microarrays. The first is the
field of diagnosis. Microarrays can be used for the detection of antigens and anti-
bodies in patient samples such as sera. Great achievements have been reported in
the field of characterisation of sera of autoimmune patients (JOOS et al., 2000; ROBIN-
SON et al.,, 2002). JOOS et al., generated protein microarrays with known autoanti-
gens and achieved a sensitive detection of autoantibodies down to 40 fg. ROBIN-
SON spotted 196 biomolecules for the characterisation of sera of eight human autoim-
mune diseases. Recent advances reported a microarray with 146 distinct antibod-
ies for the monitoring of protein levels in colon carcinoma cells (SREEKUMAR et al.,
2001). A further field in diagnosis is emerging: the monitoring of environment and
food with microarrays. SAMSONOVA et al., (2002) measured antiparasitic agents in
bovine liver down to 19.1 ng/g. The major application of protein arrays is in the basic
proteome research (GLOEKLER and ANGENENDT, 2003), including target identifica-
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tion, comparitative proteomics, functional analysis of proteins and cellular expression
profiling. Protein microarrays also have the potential for therapeutical application al-
though no application has been shown until now (GLOEKLER and ANGENENDT, 2003).
Although promising results and rapid progress in the field of protein microarrays
the technology has to face several limitations. Numerous antibodies are not suitable
for the application on arrays, due to loss of functionality and specificity. Also problem-
atic is the labelling of complex protein mixtures, due to the diversity preventing direct
coupling in defined stoichiometry. Additionally the labelling includes the danger of
changes in the structure of the proteins. Therefore the development of label free detec-
tion is essential. Furthermore the surface chemistry and material has to be optimised
to circumvent denaturing and dehydration of the immobilised proteins. The last point
is that only few antibodies in comparison to the number of proteins present in the hu-
man proteome are currently available. Technologies for the generation of antibodies
have to be adjusted with the ultimate goal to generate antibodies that cover the whole
proteome or even the epitome.
1.2 Antibodies
Antibodies (Ab) are protein molecules with a molecular weight of 150-180 kDa. They
consist of two identical light chains (23 kDa) and two identical heavy chains (50-65
kDa). The chains are covalently bound to each other via intramolecular and inter-
molecular disulfid bridges (BURTON, 1987), forming a tetramer with characteristic Y-
form (1.1). Heavy chains as well as light chains are organized in globular domains,
each composed of around 110 aminoacids. The domains share characteristic structural
features, the immunoglobulin superfold, and are stabilised via intra-chain disulfide
bonds. In case of light Ab-chains a distinction is drawn between λ chains and κ chains.
The C-terminal constant regions (C-region) of the heavy chain determine the iso-
type of the antibody (IgD, IgM, IgG, IgA or IgE type). It mediates different effector
functions as activating the complement system and binding to receptors on macro-
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phages and other cells that finally eliminate the antigen (ABBAS et al., 1994). In contrast
to the 3 (IgG, IgD, IgA) or 4 (IgM, IgE) constant domains of the heavy chain (CH1-3[4]),
light chains have only one constant domain (CL).
Based on the variability of the amino acid sequence the immunoglobulin chains
are divided into constant regions and variable regions. The variable regions of the
light chain (VL) and the heavy chain (VH) are located on the N-terminus. Together
they form the antigen binding site. The variable domains consist of three hypervari-
able regions (CDR = complementary determining region), forming α-helices, which
are each flanked and therefore stabilised by conservative regions (frameworks [FR1-
4]) with β-sheet structure (KABAT et al., 1990). Electrostatic forces, hydrophobic in-
teractions, hydrogen bonds and van-der-Waals forces lead to the binding between the
paratop of the antibody and the complementary epitope of the antigen. The specificity
of the antibody for its antigen is determined by the amino acid sequence of the CDR
(JONES et al., 1986).
The diversity of the antibody repertoire is caused by different mechanisms. First,
each antibody encoding gene is composed of several gene segments that are assembled
by somatic DNA recombination. The variable region of the light chain is coded by the
so called V (variable) and J (joining) gene segments, while the heavy chain is coded by
V-, J- gene segment and an additional D (diversity) gene segment. For each segment
a number of variations is encoded in the genome. The combinatorial diversity that is
resulting from the VDJ recombination and the indepent assembly of different light and
heavy chain variable regions to form an antigen binding structure is in the range of
3x 106. The antibody diversity is further enhanced by the randomised introduction of
additional nucleotides between the single gene segments. The overall diversity of the
naïve antibody repertoire is estimated to be around 1011 (JANEWAY et al., 2002). The
antibody affinity, the binding strength, is determined by the sum of all electrostatic
attraction and repellent forces. This sum is increased if the antigen is bound by the two
antigen binding sites of a full size antibody (Avidity).
Antibody fragments (Figure 1.1) play also an important role in the field of molecu-
lar biology with a focus on the antigen-binding regions. In the more early stages of an-
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tibody research antibody fragments were produced by proteolytic cleavage (PORTER,
1959, INBAR et al., 1972, PARHAM, 1986). The enzyme papain cuts the antibody in
front of the hinge region into two parts: the Fab (fragment antigen binding) and the
Fc (fragment crystallisable) part. The two chains of the Fab-fragment are connected
by a disulfid bridge. The enzyme Pepsin cuts after the hinge region and therefore two
Fab-fragments are linked by the hinge region. This fragment is called F(ab’)2. An alter-
native way for the construction of antibody fragments are modernmolecular biological
and protein engineering methods.
The minimum antigen-binding unit of an antibody is the Fv-fragment, which solely
consists of the associated variable domains of heavy and light chains. Due to their non-
covalent linkage they are very unstable and tend to dissociate into their subunits. The
resulting fragments can be stabilised by a short peptide linker of 15-30 amino acids
between the two domains. These fragments are called single chain antibody (scFv)
(BIRD et al., 1988). Using a shorter linker of only 3-6 amino acids prevents the intra-
molecular assembly of the two antibody chains (TODOROVSKA et al., 2001). Two VH-
VL-molecules can then associate intermolecular and form two antigen binding sites to
form diabodies (HOLLIGER und WINTER, 1997).
1.3 Generation of Antibodies
1.3.1 Hybridoma Technology
In the past the only source for antibodies was the serum of immunised animals. These
serums contain mixtures of antibodies with different binding specificities. They origi-
nate from different B-cell clones and are therefore called polyclonal antibodies. In 1975
KÖHLER andMILSTEIN (KÖHLER andMILSTEIN, 1975) developed the hybridoma tech-
nique, which for the first time allowed the generation and production of monoclonal
antibodies (mAb). This technique is based on the ability to fuse mortal B-cells with
immortal myeloma cells and therefore fuse the ability of producing antibodies with
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Figure 1.1: Structural scheme of an IgG antibody and a scFv. CH1-3 = constant region of the
antibody heavy chain, CL = constant region of the antibody light chain, VH = variable region of the
antibody heavy chain, VL = variable region of the antibody light chain, S-S = disulfide bridge, Fv =
Fragment variable, CDR = complementary determining region, Fab = Fragment antigen binding, Fc =
fragment crystallisable
.
immortality. MAb are characterised by their homogenous specificity to the epitope of
the antigen. In general, activated murine B-cells from immunised mice are used for the
fusion to generate stable antibody producing cell lines.
A good immunisation is required for the generation of monoclonal antibodies with
high affinity for the antigen of interest. The success of the immunisation depends on
several parameters, like the immunogenicity and amount of the antigen needed for im-
munisation, the route of application and the time span in which the antigen is applied
(PETERS and BAUMGARTEN, 1990). The ability of an antigen to provoke an immune
response is essential for a successful immunisation. Some proteins lack this ability, for
example proteins which are highly conserved between the species and therefore show
high degree of homology, as well as small proteins or peptides called haptens. The
amount of antigen and the route of delivery is important for a good immunisation.
Typical amounts range from < 10 µg up to 400 µg per injection (PETERS and BAUM-
GARTEN, 1990). The route of application can be oral, intramuscular, subcutaneously,
intraperitoneally or intrasplenic (PETERS and BAUMGARTEN, 1990). Many different
immunisation schemes have been described and applied successfully (RATHJEN et al.,
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1986).
The development of an immune response to an antigen is hard to predict due to the
complexity of the processes involved and immunization strategies have to be adapted
to the antigen. After successful immunisation the activated B-cells are isolated from
the spleen and fused with immortal myeloma cells. The fusion can be accomplished
chemically with PEG or by electrofusion. The fusion mechanism induced by PEG is
not completely understood but it is supposed that addition of PEG results in an aggre-
gation of membrane proteins between two or more cell by removing water molecules
on cell surfaces. The first cell divisions after the fusion are critical and only a few lead
to viable products because of the increased ploidy and number of centrioles. Success-
ful fusions of B-cells with myeloma cells are selected by a special selection medium
with HAT components (Hypoxanthin-Aminoptermin-Thymidin). Aminoptermin as a
nucleo-analog blocks the de novo pathway for the synthesis of purins and pyrimidins.
The splenic B-cells are capable of the alternative salvage pathway by using the pre-
cursors hypoxanthin and thymidin. Myeloma cells fail to use this pathway because of
a deficiency of the hypoxanthin-guanin-phosphoribosyl transferase and therefore are
unable to process these precursors. Unfused B-cells survive the selection procedure,
but they can only perform a limited number of cell divisions before they undergo apop-
tosis. Hybridoma cells, which are the fusion products of one B-cell with one myeloma
cell are viable because they obtain characteristics of both parental cells, the ability of
unlimited growth in cell culture coming from the myeloma cell on the one hand and
on the other hand the nucleotide metabolism and the capability of monoclonal anti-
body production. The surviving hybridoma are subjected to limiting dilution based
subcloning to obtain permanently growing hybridoma cell lines.
1.3.2 Phage Display Technology
The Phage Display is a newer method for the generation of antibodies in vitro. In 1985,
the isolation of antibody fragments (scFv, Fab) with specificity for a certain antigenwas
simplified by the phage display technology (SMITH, 1985). This facilitates the imitation
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of the immune system of vertebrates in vitro by mimicking the random assembley of
the variable regions as well as the affinity maturation. For this, the technology utilises
filamentous bacteriophages, for example M13 (SMITH, 1985). These bacteriophages be-
long to the single-stranded DNA viruses. The DNA is encapsulated by a long cylinder
(900 nm) of proteins. The most known proteins of the capsid are the major coat protein
pVIII (2800 copies) and the pilot protein pIII (3-5 copies). These phages reproduce in-
tracellular in bacteria which contain the F-pilus. The bacteriophage binds with its pIII
protein to the F-pilus of the bacteria and injects the viral DNA into the cell, where it is
reproduced up to 200fold following the principle of the rolling circle (STASSEN et al.,
1994-1995). The assembley of the new phage particles occurs at bacterial membranes
without lysis of the bacterial cell.
To use this system for the selection and production of antibodies the genome of
the bacteriophage was modified. The variable regions of antibody genes were isolated
from B-cells of naïve or immunised animals by PCR-amplification and subsequently
cloned as fusion partners to e.g. the phage protein pIII or other phage proteins into
phage or phagemid vectors. Phage vectors contain the complete set of the phage genes,
while phagemid vectors include only the pIII protein. The addition of helper phages
containing the remaining genes is required for the production of phages. If bacteria are
infected with the modified phage DNA, phages are produced expressing the antibody
fragments as fusion proteins with pIII at the tip of a phage. The scFv (MCCAFFERTY
et al., 1990) or Fab-fragments (HOOGENBOOM et al., 1991) are fused to the N-terminus
of the phage protein. Like B-cells in vivo each phage contains only the genetic infor-
mation for one antibody with a certain specificity. Libraries with antibody specificities
between 107-1010 can be generated (HOOGENBOOM et al., 1998)
These phages can now be selected on different antigens. Antigen specific phages
bind to the antigen, while unspecific phages are washed away. The specific phages can
be eluted from the antigen and reproduced by reinfection of bacteria. Further enrich-
ment of high affinity phages can be achieved by additional panning rounds. Finally, the
DNA of specific phages can be isolated from the phage and transferred into bacterial
or eucaryotic expression vectors for further characterisation of the antibody (WINTER
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et al., 1994).
1.4 Antigens
Various substances can act as antigens and lead to the b-cell mediated generation of
antibodies. In the following sections antigens used in this thesis are described.
1.4.1 Estrogens and Xenoestrogens
Estrogens are hormones, which regulate cell division and gene expression in females
(SOTO et al., 1991). The natural estrogen binds to the intracellular estrogen receptor
(ER), leading to an ER-estrogen-complex including an ER dimer. This complex is trans-
ported into the nucleus where it binds to the estrogen responsive element (ERE) of the
DNA upstream of estrogen regulated genes which activates the transcription of the
genes. Additionally it interacts with further transcription factors. Estrogens are re-
lated to feminine characteristics, control reproductive cycles and pregnancy, influence
skin, bone, the cardiovascular system and the immune system (TAPIERO et al., 2002).
In addition to natural estrogens there are a number of substances mimicking or
blocking the natural hormones, which are called xenoestrogens (SOTO et al., 1995).
Synthetic xenoestrogens are, for example, Bisphenol A (synthetic compound in plastic
ware), Octylphenol, Nonylphenol (detergent), DDT (pesticide) and polychlorinated
biphenyls (industrial chemicals) (AHMED, 2000). In the environment they are found in
the downfounts of sewage treatment, in sediments and surface waters of rivers.
DDT, the first compound with proven xenoestrogenic effect, leads to abnormal de-
velopment of avian embryos (SINGER, 1949). Further effects of xenoestrogens reported
are reduced fertility of birds and fish, feminisation of birds, fish and mammalians as
well as effects on the immune system of vertebrates (COLBORN et al., 1993). The estro-
genic effect of synthetic xenoestrogens is only about 10−3-10−6 of that of the natural
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estrogen, but lipophilic characteristics of the compounds and a higher persistence than
natural estrogen lead to accumulation of these substances in fat tissue and the envi-
ronment (SOTO et al., 1995). Further synergistic effects of estrogens and xenoestrogens
are reported, which are stronger than the accumulation of the single effects (SOTO et
al., 1995). There are no secured proofs for xenoestrogenic effects, like reduced fertility,
increased cancer risk, or other harmful effects on the health, of humans. The possible
impact on human health appears to be conjecturable (DEGEN and BOLT, 2000).
Nonylphenol is the generic name for substances with the chemical formula C6H4
(OH)C9H19. Technically Nonylphenol consists mainly of a phenol which is substituted
in para-position with side chains of different degrees of branching. It belongs to the
class of alkylphenols (AP), which are used for the synthesis of alkylphenolpolyethoxy-
lates (APE). APE are mainly used in industrial applications as elastomers, textiles,
agricultural chemicals and paper products. Also high amounts are used in industrial
cleaning products, household cleaning and personal care products (TALMAGE, 1999).
In 1997, the total EU production of Nonylphenol was 73,500 tonnes, exports were
about 3,500 tonnes and imports were about 8,500 tonnes. The total EU consumption
of Nonylphenol was estimated to be 78,500 tonnes (Environmental Health Department
Ministry of the Environment Government of Japan, 2001). Local releases of Nonylphe-
nol to the environment may occur during production, use as a chemical intermediate
and from the breakdown of Nonylphenol ethoxylates in wastewater treatment plants.
Nonylphenol is one of the major biodegradation products of APE. Most of the AP pro-
duced during the degradation of APE is absorbed to solids, leading to a high amount
of these chemicals in sewage sludge in the range of grams per kilogram (ZERAVIK et
al., 2004). Nonylphenol is persistent in the environment and shows high toxicity due
to accumulation in aquatic organism, mammals and birds (TSUDA et al., 2001; ISOBE
et al., 2001). It was also found as an air pollutant in urban atmosphere, probably due
to evapourisation from the Hudson River (DACHS et al., 1999). Nonylphenol is an ubi-
quitous pollutant of the aquatic environment reaching concentration of microgram per
litre. It is found in sediment as well as in surface water (FUJII et al., 2000).
Nonylphenol is considered to be an endocrine disrupting substance, mimicking
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the female sex hormone estrogen. Already in the late 1930s estrogenic effects of APs
including also Nonylphenol were reported (DODDS and LAWSON, 1938) and later in
1978 (MUELLER and KIM, 1978) further data were published. Estrogenic effects on the
growth of human breast cancer cells (SOTO et al., 1991) in concentrations of 1,000-10,000
higher than natural estrogens were proven. Estrogenic effects are present at tissue con-
centrations of 1 µM for Nonylphenol (SOTO et al., 1995). The binding of Nonylphenol
and other AP to the estrogen receptor leads to several reponses shown both in a series
of in vitro and in vivo assays, like the induction of vitellogenin expression (TAPIERO et
al., 2002). Estrogenic effects have also been reported on rainbow trout hepatocytes and
a mouse estrogen receptor (WHITE et al., 1994).
Natural hormones are not persistent in the environment. They are short-lived and
therefore do not accumulate in tissues. They are easily broken down in the liver. In
contrast to that NP and other estrogen-like acting chemicals and drugs are much more
stable and tend to accumulate in the body, particular in fat tissue due to the lipophilic
character of these compounds (TAPIERO et al., 2002). Thus, depending on the natural
estrogen levels, environmental estrogens may have different influences on estrogen
activities. These facts published in the last years led to health concerns and restrictions
concerning the use of AP in industry andwill lead to further tests and risk assessments.
1.4.2 Lung Cancer
Lung cancer is one of the leading causes of death in Germany and ranks at position 2
of the most frequent kinds of cancer in case of men (http://www.rki.de). The overall
5-year survival rate after diagnosis is only 10-15% (SEKIDO et al., 1998). Lung cancers
are broadly categorised into two histological groups, the small cell lung cancer (SCLC)
and non-small cell lung cancer (NSCLC), respectively. SCLC is prognosed in 20% to
25% of all cases, NSCLC in 75% to 80% of all cases (MCDONIELS-SILVERS et al., 2002).
NSCLC is further divided into three subgroups: squamous cell carcinoma (25%), ade-
nocarcinoma (30%) and large cell carcinoma (10%) (MCDONIELS-SILVERS et al., 2002).
The main cause for lung cancer is smoking and (professional) dust exposure.
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Current tools for diagnosis of lung cancer are computer tomography (CT), sonogra-
phy, bone-scintigraphy, bone marrow biopsy. As therapy resection of the tumor in case
of NSCLC, chemotherapy as well as radiotherapy is used. Tumor markers may play
an important role, not only in basic research, but also for the clinician in diagnosis and
treatment of cancer (PAMIES and CRAWFORD, 1996). Tumor-associated markers can be
used for diagnosis, localisation and therapy. Plasma levels of serum tumor markers
may reflect both stage of disease and prognosis. They may aid in assessing responses
to therapeutic interventions (COOMBES and POWELS, 1982). Lung tumor markers fall
into several categories, which are listed in table 1.1 (BUCCHERI, 1999).
Table 1.1: Classification of lung tumor markers
Classification Tumor marker Annotation Reference
Hormones β-HCG human chorionic
gonadotropin
WALOP et al., 1990
Gastrin releasing
peptide (GRP)
marker for SCLS SCHNEIDER et al., 2003
Oncofetal proteins Carcinoembryonic
antigen (CEA)
glycoprotein on epithelial
cells; cell-cell-contact;
protection against
bacteria
GOLD and FREED-
MAN, 1965
Structural proteins Tissue Polypeptide
Antigen (TPA)
complex of fragments of
cytokeratins 8, 18 and 19
BUCCHERI, 1999
Cyfra 21-1 Cytokeratin 19 fragment
released in bloodstream
because of cell lysis and
tumor necrosis
BROERS et al., 1988
Tissue Polypeptide
specific Antigen (TPS)
Epitope on CK-18
recognized by antibody
M3
PUJOL et al., 1994
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Classification Tumor marker Annotation Reference
Enzymes Neuron-specific
Enolase (NSE)
glycolytic enzyme; serum
level elevated in cancer
patients
KULPA et al., 2002
Lactate
dehydrogenase (LDH)
serum biomarker KOUKOURAKIS et al.,
2003
Creatin-
phosphokinase
isoenzyme BB
(CPKBB)
enhanced enzyme release
as a result of tumour cell
necrosis
JOSEPH et al., 1997
Cyclooxygenase
(COX-2)
DUBINETT et al., 2003
Farnesyltransferase ADJEI et al., 2003
Membrane
Antigens
Neural cell adhesion
molecule (NCAM)
potential marker for
diagnosis of SCLC
JAQUES et al., 1993
soluble Interleukin-2
receptors (sIL2-R)
released by activated
mononuclear cells
NAUMNIK and CHY-
CZEWSKA, 2001
EGFR (epidermal
growth factor
receptor)
increased expression DEEB et al., 2004
E-cadherin cell adhesion molecule
decreased expression
DEEB et al., 2004
Other
tumor-associated
antigens
Squamous Cell
Carcinoma Antigen
(SCC-Ag)
MOLINA et al., 2003
CA 125 membrane glycoprotein BUCCHERI, 2002
CA 19-9 carbohydrate antigenic
determinant
NIKLINSKI et al., 1992
CA 242 carbohydrate antigen HASHOLZNER et al.,
1999
CA 15-3 carbohydrate antigen STIEBER et al., 1993
Chromogranin A JOHNSON et al., 1993
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There are two major problems in the field of lung cancer diagnosis. None of these
tumor markers mentioned in table 1.1 is exclusively specific for lung cancer. Most
diagnosis and analysis assays use a combination of different tumor markers, which
mark also other malignant diseases. Furthermore in most cases when lung cancer is
diagnosed the disease is at an advanced stage. Early symptoms correlate with symp-
toms of a common cold. As a result of this the 5-year survival rate is extremely low.
According to this, the early detection and risk modification of lung cancer remain elu-
sive problems and in the future it is important to develop a new and extreme sensitive
diagnostic tool for early stages of lung cancer (WARDWELL and MASSION, 2005).
1.4.3 Pancreas and Pancreatic Cancer
The pancreas is situated at the abdominal wall under the diaphragm. This gland is
divided into two parts due to different functions: the exocrine and the endocrine part.
The endocrine part is formed by the Langerhansche islands. Different cell types are
responsible for the production of four different hormones (insulin, glykagon, somato-
statin and pancreatitic polypeptide), which control the level of blood sugar, the produc-
tion of digestive juices as well as the digestion. The exocrine gland produces digestive
enzymes like proteases, amylase and lipase (ISENMAN et al., 1999).
Malignancies of the pancreas are in most cases located inside the exocrine gland.
Pancreatic cancer shows a very aggressive growth and tends to develop extensive local
invasion and metastasises in early stages. The frequency is about 10 new cases of
100,000 persons per year in Germany, which is only 2%-3% of all cancer carcinoma
(http://www.rki.de). Although it does not belong to the most frequent cancers it ranks
at position 4 of the most frequent causes of cancer related deaths worldwide (JEMAL
et al., 2003). The 5-year survival rate is only 2%-3% and the median survival time after
diagnosis is 4-6 month (LI et al., 2004). Early stages are often free of symptoms and
therefore it is diagnosed too late in an advanced stage of development. Furthermore
the tumors are in most cases resistant to chemotherapy and radiotherapy. For only
15% of the patients a curative resection at the time of diagnosis is feasable (WELZEL
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et al., 2003). Treatment by resection is only possible if the tumour is not metastasised,
otherwise complete healing is impossible. Partial resection is possible and is performed
if complete resection is not possible.
Current diagnostic tools are computer tomography (CT), ultrasonic test ing (sonog-
raphy, Endosonography) and endoscopic retrograde cholangiopancreaticoscopy (ER-
CP). Radiotherapy as well as chemotherapy is mostly used in combination for pallia-
tive therapy.
A number of genes have been reported to be over-expressed or mutated in pancre-
atic cancer like mesothelin, MUC-4, S100A8, Transglutaminase 2 (IACOBUZIO-DONA-
HUE et al., 2003; SHEKOUH et al., 2003; SHEN et al., 2004), K-ras, p16, BRCA2, HER2/neu
and p53 (LI et al., 2004). But so far only a few turned out to be valuable as diagnostic
markers. To date the most commonly used biomarkers for diagnostic purposes are the
carbohydrate antigens 19-9 and 242 (KAWA et al., 1994; FURUYA et al., 1996) and the
tumor specific growth factor (TSGF) (J IANG et al., 2004). Although these markers show
good specificity in the diagnosis of tumours in advanced stages, they are not useful
early stage diagnosis. Additional difficulties appear in the failure of the biomarkers to
discriminate between chronic pancreatitis and pancreatic cancer, which show the same
clinical appearance (EBERT et al., 2001). This emphasises the need for development of
new diagnostic tools for the early detection and discrimination of pancreatic cancer.
1.5 Objectives
1.5.1 AGESSA
This thesis is divided into two projects. The schematic overview of the thesis is shown
in figures 1.2-1.4. The first project is embedded in the Graduate College for the Elimi-
nation of Endocrine Disrupting Substances fromWaste Water (AGEESA). The aimwas
to generate an antibody against Nonylphenol (NP), which can be used for the gen-
eration of biofilters for the effective elimination of NP from waste water in the fu-
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ture. NP is too small to provoke an immune response itself. To raise an immune
response against the phenolic hapten NP it had to be conjugated to an immunogenic
carrier protein (cationised BSA = cBSA). Because most proteins contain both exposed
lysines and carboxyl groups, EDC (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide)
mediated immunogen formation is a simple method for the majority of protein-carrier
conjugations. NP itself contains no reactive group for EDC mediated coupling. For
this reason the derivate 9-(4-Hydroxyphenyl)-nonanacid had to be synthesised. Af-
ter successful immunisation of mice with the conjugated NP-carrier monoclonal anti-
bodies were generated by B-cell fusion with Sp2/mIL-6 myeloma cells. Cloning of the
hybridoma clones was carried out using fluorescent activated cell sorting (FACS). An-
tibodies showing binding activity in ELISA were further characterised.
Sythesis of Nonylphenol-Derivate- -
Coupling of the Hapten to Carrier- - - - -
Immunisation
Generation of Hybridoma Cells- - -
Pre-selection and Cloning- -
Propagation of Single Cells- - -
Characterisation of mAb- -
Figure 1.2: Scheme of the generation of a monoclonal antibody against NP.
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1.5.2 Systemised Approach for High-Throughput Generation of An-
tibodies and Identification of the Corresponding Antigens
The objective of the second project was the establishment of a process suitable for the
industrial high throughput generation of antibodies against every protein in the hu-
man proteome. The long term goal of the whole project is to generate antibody mi-
croarrays for the screening of patient samples in comparison to controls in parallel to
generate statistically evaluated disease protein signatures and therefore provide anti-
body microarray based diagnostic tools for the early diagnosis of diseases. To reach
this goal ten thousands of antibodies have to be generated. As proof of principle, an-
tibodies against proteins present in complete tissue and cell lysates respectively of the
lung and pancreas were generated. Due to this randomised approach the specificty
of these antibodies is unknown until this timepoint. Therefore the generation of the
antibodies is followed by the identification of the corresponding antigen. The random
generation of large repertoires of antibodies against complete protein mixtures of the
pancreas and the lung on a proteome wide basis should in the long term lead to the
discovery of new sets of biomarkers for the diagnosis of diseases. Combining several
antibodies directed against potential marker molecules on a protein microarray should
allow the detection of complex disease specific protein expression patterns and greatly
support the diagnosis of pancreatic or lung cancer.
Two different set ups were be tested in the scope of this thesis. The first set up
utilises 2D-PAGE and phage display technology (Phage Display Approach). Cell lysate
samples are separated by 2D-PAGE and subsequently blotted onto membrane. These
membranes are incubated with phages from a naïve scFv library and specifically bind-
ing phages are identified and eluted from membrane. The corresponding protein spot
on the gel should be identified by MS analysis.
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Sample Preparation-
2-dimensional Electrophoresis/
Western Blot
-
-
Selection by Phage Display- - -
Phage Recovery-
Characterisation of Phages- -
Spot Picking from 2D-PAGE- - -
Antigen Identification-
Figure 1.3: Schematic presentation of the phage display approach.
The second approach employs the hybridoma technology (Hybridoma approach).
Mice are immunised with either cells, cell lysate and tissue lysate. After successful
immunisation, monitored by ELISA, the B-cells are fused with myeloma cells. Due
to the lack of well defined proteins, as used in traditional hybridoma technology, a
pre-selection procedure had to be established for the hybridoma by incubation with
fluorescently labelled protein solution and subsequent single cell sorting using FACS.
Therefore, single hybridoma cell culturing had to be established. Finally an approach
had to be developed for the immunoprecipitation of the antigen followed by identifi-
cation via MS. Interesting antibody-antigen pairs are further characterised using e.g.
molecular imaging.
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Sample Preparation-
Immunisation of Mice- -
Generation of Hybridoma Cells- - -
Pre-selection and Cloning- -
Propagation of Single Cells- - -
Antigen Identification-
Characterisation of Antibody-
Antigen-Pair
- -
Figure 1.4: Schematic presentation of the hybridoma approach.
Chapter 2
Material and Methods
2.1 Material
2.1.1 Chemicals and Consumables
Unless otherwise stated chemicals and consumables were purchased from Abbott (Illi-
nois, USA), Amersham Biosciences (Freiburg), Becton Dickinson Bioscience (Franklin
Lakes, USA), Biochrom (Berlin), BioRad (Munich), Biozym (Oldendorf), Caltag (Ham-
burg), Chemicon (Hofheim), Cytogen (Obermoerlen), Dynal (Hamburg), Dyomics (Je-
na), Eppendorf (Hamburg), Gerbu (Heidelberg), Gibco BRL (Eggenstein), Greiner (So-
lingen), Hewlett-Packard (Munich), Kisker Biotech (Muehlhausen), Kodak (Stuttgart),
Invitrogen (Eggenstein), Merck Bioscience (Bad Soden), Millipore (Eschborn), Mole-
cular Probes (Invitrogen, Karlsruhe), New England Biolabs (NEB) (Schwalbach), Nunc
(Biebrich), Pall Filtron (Northborough, MA, USA), Pierce (Rockford, USA), Promega
(Mannheim), Qiagen (Hilden), RocheMolecular Biochemicals (Mannheim), Roth (Karl-
sruhe), Schott-Glaswerke GmbH (Neufahrn/San Diego), Serotec (Duesseldorf), Sigma
(Deisenhofen), Starlab (Ahrensburg), VWR (Darmstadt), Whatman (Maidstone, Eng-
land) and Zeiss (Oberkochen).
2.1.2 Media, Stock solutions and Buffers
Standard media and stock solutions were prepared according to standard procedures
(SAMBROOK et al., (1996), AUSUBEL et al., (1995) or COLIGAN et al., (1995) using de-
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ionised water. Solutions were sterilised by autoclaving (25 min/121◦C/2 bar). Heat-
sensitive components were prepared as stock solutions, filter-sterilised (0.2 µm) and
added to the medium/buffer after cooling to 50◦C.
2.1.2.1 General Recipes
10x PBS, pH 7.4 PBST
NaCl 1.37 M 1x PBS (pH 7.4)
KCl 27 mM Tween 20 0.05% (w/v)
KH2PO4 15 mM
Na2HPO4 x 12H2O 81 mM
50x TAE Electrophoresis Buffer (pH 7.5) 5x OrangeG Loading Buffer
Tris-Base 2 M OrangeG 0.1% (w/v)
Glacial acetic acid 5.7% (v/v) Glycerol 30% (v/v)
EDTA 50 mM in 1x TAE buffer
5x SDS PAA Running Buffer Blotting Buffer
Tris-HCl (pH 8.3) 125 mM Tris-HCl (pH 8.3) 25 mM
Glycine 960 mM Glycine 192 mM
SDS 0.5% (w/v) Methanol 20% (v/v)
Coomassie Staining Solution Coomassie Destaining Solution
Coomassie bb. G-250 0.25% (w/v) Methanol 10% (v/v)
Methanol 50% (v/v) Glacial acetic acid 10% (v/v)
Glacial acetic acid 9% (v/v)
Tetramethyl benzidine (TMB) stock TMB working solution
TMB 240 mg TMB stock 100 µl
DMSO 5 ml NaAc (100 mM, pH 6.4) 10 ml
store at 4◦C 30% H2O2 5 µl
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5x Reducing Protein Loading Buffer 5x Non-Reducing Loading Buffer
Tris-HCl (pH 6.8) 62.5 mM Tris-HCl (pH 6.8) 62.5 mM
Glycerol 30% (v/v) Glycerol 30% (v/v)
SDS 4% (w/v) SDS 4% (w/v)
Bromphenolblue 0.05% (w/v) Bromphenolblue 0.05% (w/v)
ß-Mercaptoethanol 10% (v/v)
NuPAGE
R© SDS Running Buffer NuPAGE
R© Sample Preparation
20x NuPAGEMES 50 ml Sample x µl
dH2O 950 ml NuPAGE LDS buffer 2.5 µl
(200 ml buffer +500 µl anti- NuPAGE reducing agent 1 µl
oxidant) dH2O ad 10 µl
AP Buffer (pH 9.6) ELISA Coating Buffer (pH 9.6)
Tris-HCl (pH 9.6) 100 mM Na2CO3 15 mM
NaCl 100 mM NaHCO3 35 mM
MgCl2 5 mM
FACS Buffer 2D-PAGE Rehydration Buffer
1x PBS (pH 7.4) Urea 9 M
BSA 0.2% (w/v) CHAPS 4% (w/v)
Sodium azid 0.05% (w/v) DTT 25 mM
Ampholyte (pH 3-10) 1% (v/v)
Bromphenolblue 1 µl
2D-PAGE Equilibration Buffer SDS-PAA-Gels
Urea 9 M Stacking gel: T=4%, C=2,7%, pH 6,8
Glycerol 30% (w/v) Running gel: T=12%, C=2,7%, pH 8,8
SDS 2% (w/v)
Tris-HCl (pH 8.8) 0.05 M
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2.1.2.2 Media for Cultivation of Mammalian Cells
RPMI (SF) RPMI (C)
RPMI 1640 RPMI (SF)
(Cytogen or Gibco) FCS 10% (v/v)
Penicillin 50 µg/ml
Streptomycin 50 µg/ml
L-Glutamine 2 mM
RPMI (20%) RPMI (15%)
RPMI (SF) RPMI (SF)
FCS 20% (v/v) FCS 15% (v/v)
Penicillin 50 µg/ml Penicillin 50 µg/ml
Streptomycin 50 µg/ml Streptomycin 50 µg/ml
L-Glutamine 2 mM L-Glutamine 2 mM
HAT RPMI (CGP)
RPMI (20%) RPMI (SF)
HATMedia Supplement Glucose 4.5 g/L
Hybri-Max R© (Sigma) 1x Sodium pyruvat 1 mM
HT CD (C)
RPMI (20%) CD Hybridoma (Gibco)
HT Media Supplement Penicillin 50 µg/ml
Hybri-Max R© (Sigma) 1x Streptomycin 50 µg/ml
L-Glutamine 2 mM
F12 Cryo-conservation medium
FCS 10% (v/v) RPMI (20%)
L-Glutamine 2 mM DMSO 10% (v/v)
Sodium bicarbonate 1.5 g/L
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Media supplements:
BM Condimed H1 (Hybridoma Cloning Supplement) (Roche) 10% (v/v)
Unless purchased sterile, all media, solutions and supplements used in cell culture
work were sterilised with a 0.2 µm syringe filter, stored at 4◦C and prewarmed to 37◦C
prior to use.
2.1.3 Derivative of Nonylphenol
The 9-(4-Hydroxyphenyl)-nonanacid (NP-COOH) (2.1) was kindly synthesised and
provided by Prof. Bolm and Mr. Classen (Institute of Organic Chemistry, RWTH Uni-
versity).
Figure 2.1: 9-(4-Hydroxyphenyl)-nonanacid (NP-COOH) .
2.1.4 Enzymes and Reaction Kits
Porcine Trypsin (Promega) and Bovine Trypsin (Roche) were used for protein digestion
prior to Mass Spectrometry (2.2.6).
Imject R© SuperCarrier R© EDC System (Pierce) (Pierce, Rockford, USA) was used for
coupling of 9-(4-Hydroxyphenyl)-nonanacid (2.1.3) to cBSA (2.2.2.3). The BD Phar-
migen mouse Ig ELISA isotyping kit was used for the determination of the isotype of
monoclonal antibodies.
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2.1.5 Primer
Oligonucleotides for use in PCR were purchased from MWG Biotech:
Table 2.1: Compendium of used oligonucleotides
Name Sequence
pHEN3’ back 5’ - GAC GTT AGT AAA TGA ATT TTC - 3’
LMB3 5’ - CAG GAA ACA GCT ATG AC - 3’
fdseq1 5’ - ACG TTA GTA AAT GAA TTT TC - 3’
2.1.6 Affinity Beads
• Dynabeads R© Protein G (Dynal Biotech)
• Dynabeads R© Protein A (Dynal Biotech)
• Goat anti mouse IgG H+L magnetic particles (Kisker)
2.1.7 Antibodies
Table 2.2: Compendium of used antibodies
Antibody Epitop Characteristics
goat-anti-mouse IgG
[GAMHRPO(IgG Fc)]
(Sigma)
Fc of mouse IgG polyclonal, conjugated to
Horseradish peroxidase
(HRPO)
goat-anti-mouse IgG
[GAMAP (IgG Fc)] (Sigma)
Fc of mouse IgG polyclonal, conjugated to
Alkaline phosphatase (AP)
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Antibody Epitop Characteristics
F(ab’)2 goat anti mouse
IgG [GAMAP (IgG H+L)]
(Sigma)
heavy und light of
murine IgG
polyclonal, conjugated to
AP
F(ab’)2 goat anti mouse
IgG [GAM(IgG)] (Serotec)
murine IgG polyclonal
Goat anti mouse IgM
[GAM(IgM)] (Serotec)
murine IgM polyclonal
F(ab’)2 goat anti mouse
IgG [GAMHRPO(IgG)]
(Serotec)
murine IgG polyclonal, conjugated to
HRPO
Goat anti mouse IgM
[GAMHRPO(IgM)]
(Serotec)
murine IgM polyclonal, conjugated to
HRPO
Goat anti mouse IgG/IgM
[GAMHRPO(IgG/IgM)]
(Sigma)
murine IgG and IgM polyclonal, conjugated to
HRPO
F(ab’)2 sheep anti mouse
Ig (SAMPE) (Chemicon)
murine Igs polyclonal, conjugated to
Phycoerythrin (PE)
F(ab’)2 sheep anti
mouse Ig (SAMFITC)
(Chemicon)
murine Igs polyclonal, conjugated to
Fluoreszeinisothiocyanat
(FITC)
Goat anti mouse Ig
(GAMAlexa488) (Molecular
probes)
murine Igs polyclonal, conjugated to
Alexa488
H22 (Medarex, Princeton,
US) hIgG1/κ
extracellular domain
of CD64
human monoclonal IgG
CA19-9 mIgG1/κ (pro-
vided by A. Paetz, RWTH-
Aachen)
tumor marker carbo-
hydrate antigen 19-9
murine monoclonal IgG
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2.1.8 Phage and Phage Display Library
M13KO7 helper phage (Amersham Biosciences) is an M13mp1 derivative containing
a modified gene 11. This gene is modified by replacing the guanin at position 6125 to
thymidin, giving a methionine to isoleucine change at codon 40. The p15A origin of
replication and the kanamycin resistance gene from Tn903 are present in M13KO7.
For selection on lung tumor cell lines a human naïve scFv-Phagemid-library was
used. This library was constructed by Dr. R. Finnern (Fraunhofer IME, unpublished
data).
2.1.9 Bacterial Strain
The following strain was used for Phage-Display (2.2.7):
• TG1: supE thi-1 ∆(lac-proAB) ∆(mcrB-hsdSM) 5(rK
− mK
−) [F´traD36 proAB
lacIq Z∆M15] (Stratagene, USA)
2.1.10 Mammalian Cell Lines
The following cell lines were purchased from the American Type Culture Collection
(ATCC) (LGC Promochem, Wesel) :
• H1373: ATCC-Nr. CRL-5866; tissue: human lung adenocarcinoma; adherent
growing (NN, 1996).
• H526: ATCC-Nr. CRL-5811; tissue: variant small cell lung cancer, derived from
metastatic site in bone narrow; in suspension growing (TAKAHASHI et al., 1989).
• HFL1: ATCC-Nr. CCL-153; tissue: human lung; adherent growing fibroblasts
(BREUL et al., 1980).
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• Sp2/mIL-6: ATCC-Nr. CRL-2016; cell type: murine myeloma cell line; derived
from Sp2/0 cells transfected with high-titer L6PNL recombinant retrovirus car-
rying a mouse interleukin-6 (IL-6) cDNA. These cells secrete constitutively large
quantities of mouse IL-6 (10000 units/ml) while growing in suspension (HARRIS
et al., 1992).
• LS174T: ATCC-Nr. CRL-188; tissue: human colon carcinoma; adherent growing
(TOM et al., 1976).
2.1.11 Equipment and Applications
• Cameras: UV-Transilluminator, Photodocumentation-System 299 and E.A.S.Y.
429K camera (Herolab, Wiesloch)
• Casy Cell Counter (Schaerfe System, Reutlingen)
• Centrifuges: AvantiTM J-30, AllegraTM 6KR (Beckman, California, USA), Eppen-
dorf-centrifuge 5415D (Eppendorf, Hamburg), Picofuge (Stratagene, USA), Roti-
labo centrifuge with Butterfly-Rotor (Roth, Karlsruhe), Biofuge primco R (Her-
aeus, Hanau)
• DADE Serocent cell washer (Baxter, USA)
• Easypure UV/UF Watersystem (Werner GmbH, Leverkusen)
• Eppendorf Concentrator 5301 (Eppendorf, Hamburg)
• Eppendorf Thermomixer compact (Eppendorf, Hamburg)
• FACSCalibur, FACSVantage SE (Becton Dickinson Bioscience, Heidelberg)
• Gel electrophoresis and electroblotting equipment: Mini Protean III gel chamber
(BioRad, Munich), XCell II Blot Module (Invitrogen, Eggenstein), Mini PRO-
TEAN IITM , Gel Air Dryer, Protean IEF cell (BioRad, Munich)
• Incubators: Hera Cell and Function Incubator (Heraeus, Hanau), InnovaTM 4430
and InnovaTM 4000 incubator shaker (News Brunswick Scientific, Nuertingen),
Julabo F32 (Julabo, Seelbach)
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• Laminar-Flow: Hera Safe HS12 (Kendro, Hanau)
• Microscope: DM R Fluorescence Microscope (Leica, Solms)
• PCR-Thermocycler: Primus 96 Plus (MWG-Biotech, Ebersberg)
• Photometer: Biophotometer (Eppendorf, Hamburg), Multichannel Photometer
(SpektraMax 340, Molecular Devices)
• Vortex-Genie 2 (Scientific Industries Inc., Bohemia, USA)
2.1.12 Laboratory Animals
For the immunisation and generation of monoclonal antibodies, 6-8 weeks old, female
BALB/c mice (Charles River, Denmark) were used (Proposal for animal experiments:
No. 1244).
2.1.13 Approbation for the Conducted Work
The approbation for the conducted work at security level S1 was given by the “Landes-
umweltamt NRW”. Number of registration is: 64-K-1.19/02.
2.2 Methods
2.2.1 Recombinant DNA Technologies
General recombinant DNA techniques including restriction digest and DNA agarose
gel electrophoresis were performed according to the standard protocols described by
SAMBROOK et al. (1996).
2.2.1.1 Polymerase Chain Reaction
Polymerase chain reaction (PCR), a procedure for rapid in vitro enzymatic amplifica-
tion of a specific segment of DNA (SAIKI et al., 1985), was used for the amplification
of scFv genes out of phagemid vectors. The reactions were performed in 0.2 ml PCR
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tubes (Biozym), using a PCR thermocycler (MWG Biotech). Bacterial clones harbour-
ing plasmid DNA containing the gene of interest were identified by PCR as described
by JESNOWSKI et al. (1995). Single colonies were picked with sterile toothpicks and the
bacteria loaded toothpicks were dipped into a PCR tube containing 50 µl of PCR mix
each (Table 2.3). Specific primers annealing to the vector backbone were used for PCR
reaction (Table 2.1.5). Thermocycler conditions were used as described in table 2.4. The
PCR products were analysed on a 1.2% agarose gel (2.2.1.2).
Table 2.3: Composition of the PCR reaction.
Components Concentration/Volume
Primer 10 pmol each
MgCl2 50 mM
dNTP-Mix 0.4 mM/dNTP
10x PCR buffer 1x
Taq DNA Polymerase (5 U/µl) 1 U
destilled water ad 50 µl
Table 2.4: PCR-Conditions for check-PCR of bacteria colonies
Step Temperature [◦C] Time
Initial denaturation 95 10 min
30 Cycles:
Denaturation 95 30 sec
Primer annealing 55 30 sec
Elongation 72 1 min
Final elongation 72 1 min
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2.2.1.2 Agarose Gel Electrophoresis
PCR fragments (2.2.1.1) and digested DNA (2.2.1.3) were electrophoretically separated
on 1-2% (w/v) analytical agarose gels prepared in TAE buffer (2.1.2.1) containing 0.1
g/ml Ethidium Bromide. 500 ng of DNA molecular marker (2-log-ladder, NEB) were
used for evaluation of sample size and integrity. The DNA was visualised on an UV
transilluminator at 302 nm and documented by a black and white E.A.S.Y 429K camera
(Herolab).
2.2.1.3 Restriction Digest of DNA
Restriction endonucleases and appropriate buffers were obtained from NEB. Restric-
tion digest and double restriction digest of DNA were performed according to the
manufacturers’ protocol.
2.2.2 Protein-Chemistry Methods
2.2.2.1 Preparation of Cell Lysates
Lysates of mammalian cells were prepared by chemical lysis. Briefly, thawed cell pel-
lets were suspended in 3% (v/v) IP-Gal and lysis buffer, respectively. Insoluble cell
debris were removed by centrifugation (8000 g/2 min/RT). Buffer of protein solution
was changed by PD10-column against PBS (Amersham Biosciences) or dialysis against
PBS (2.1.2.1) and stored at -20◦C. Protein concentration was determined using a Brad-
ford assay (2.2.5.1). Lysate was used for 2D-PAGE (2.2.5.2), immunisation (2.2.3), lysate
staining (2.2.2.4), fluorescent activated cell sorting (FACS) (2.2.5.9) and antigen capture
(2.2.5.10).
Lysis Buffer
Urea 9 M
CHAPS 4% (w/v)
DTT 65 mM
Protease Inhibitor Cocktail (Roche) 1 tablet in 50 ml buffer
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2.2.2.2 Preparation of Tissue Lysates
Lysate of human lung tissue was prepared by chemical lysis. Briefly, thawed small
tissue pieces were suspended in 3% (v/v) NP40 and lysis buffer (2.2.2.1), respectively.
Tissue was homogenised using an Ultrathorax. Insoluble debris were removed by cen-
trifugation (8000 g/5min/4◦C). The buffer of protein solution was exchanged by using
PD10-column (Amersham Biosciences) and PBS (2.1.2.1) and stored at -20◦C. Protein
concentration was determined by Bradford assay (2.2.5.1). Lysate was used for lysate
staining (2.2.2.4), FACS (2.2.5.9) and antigen capturing (2.2.5.10).
2.2.2.3 Coupling of Nonylphenol to cBSA
For subsequent immunisation of mice the hapten nonylphenol (NP) was coupled to
cationised BSA (cBSA) (Pierce). For this purpose the Imject R© SuperCarrier R© EDC Sys-
tem (Pierce) (2.1.4) was used according to manufacturers’ instructions. Briefly 0.5 µg
of the NP-derivate (NP-COOH) was solved in 200 µl DMSO and 300 µl conjugation
buffer. This solution was mixed with 2 mg cationised BSA (cBSA) in 200 µl dH2O. Re-
action was started by adding 0.1 mg 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
(EDC). Purification of the coupled product (NP-cBSA) was performed according to
manufacturers’ protocol.
2.2.2.4 Fluorescent Labelling of Protein Solutions
Protein solutions (2.2.2.1, 2.2.2.2, 2.2.2.3) were fluorescently labelled with EVOblue
TM30 (Dyomics) or CY5 (Amersham Biosciences) according to manufacturers’ instruc-
tions. The dyes were covalently coupled to primary amines via NHS-(N-Hydroxy-
succinimidyl-ester)-group. Labelled proteins were seperated from unbound dye by
PD10-columns (Amersham Biosciences) and subsequently used for antigen specific
single cell sorting of hybridoma clones (2.2.5.9).
2.2.3 Immunisation of Mice
Two mice each were immunised with cell lysate (2.2.2.1), whole cells (2.1.10) or tissue
lysate (2.2.2.2, diploma thesis F. Kampmeier). Three mice were immunised with NP
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(2.2.2.3) using different immunisation-schemes (Table 2.7). Gerbu MM (Gerbu) was
added as adjuvant. The route of immunisation was subcutaneously (sc) at different
concentrations. The immunisation scheme is shown in table 2.5 and table 2.6. Success
of immunisation was controlled 7 days after each boost by taking 10 µl of blood sample
from the tail vein. Samples were added to 10 µl PBS, centrifuged (13000 g/2 min/RT)
and supernatant (serum) was stored at -20◦C until further analysis by ELISA (2.2.5.6).
Table 2.5: Immunisation scheme with cell lysate and cells
Boost Cell Lysate Cells
Priming (day 0) 100 µg protein + 40 µl adjuvants 5x 106 cells
1st (day 21) 50 µg protein + 20 µl adjuvants 5x 106 cells
2nd (day 42) 50 µg protein + 20 µl adjuvants 5x 106 cells
3rd (day 63) 50 µg protein + 20 µl adjuvants 5x 106 cells
4th (day 84) 50 µg protein 5x 106 cells
Table 2.6: Immunisation scheme with tissue lysate
Boost Tissue Lysate
Priming (day 0) 100 µg protein
1st (day 14) 100 µg protein
2nd (day 28) 100 µg protein
3rd (day 42) 100 µg protein
4th (day 56) 100 µg protein
5th (day 126) 100 µg protein
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Table 2.7: Immunisation scheme with NP
Day Tolerisation 1 (T1) Tolerisation 2 (T2) Control (C)
1 250 µg cBSA 250 µg cBSA -
7 250 µg cBSA 250 µg cBSA -
18 100 µg NP-cBSA +
40 µl adjuvants
10 µg NP-cBSA +
40 µl adjuvants
100 µg NP-cBSA +
40 µl adjuvants
32 50 µg NP-cBSA +
20 µl adjuvants
10 µg NP-cBSA +
20 µl adjuvants
50 µg NP-cBSA +
20 µl adjuvants
46 50 µg NP-cBSA +
20 µl adjuvants
10 µg NP-cBSA +
20 µl adjuvants
50 µg NP-cBSA +
20 µl adjuvants
2.2.4 Mammalian Cell Culture Methods
General cell culture work was performed under sterile conditions under a laminar flow
hood using sterile disposable plastic ware.
2.2.4.1 Culturing of Mammalian Cells
Cell lines (2.1.10) were placed in polystyrene culture flasks (Greiner) provided with
0.2 µm hydrophobic vent caps and maintained in a humidified 5% CO2 atmosphere in
an incubator at 37◦C. All culture media were supplemented with antibiotics to avoid
bacterial contamination (2.1.2.2). Before use, FCSwas treated for 30 min at 56◦C to inac-
tivate mycoplasm and stored at –20◦C. Adherent cells were cultured until a confluence
of 70-90% and subsequently detached with a cell scraper, whereas suspension cells
were cultured to a density of approximately 106 cells/ml. Cells were harvested by cen-
trifugation (250 g/5 min/RT). The supernatant was removed and cells were washed
by resuspension in PBS with subsequent centrifugation. For subculturing cells were
diluted approximately 1:5fold with fresh medium.
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2.2.4.2 Freezing and Thawing of Mammalian Cells
Cells were harvested at a concentration of 106-107 cells/ml, washed with PBS and re-
suspended in 2-5 ml cryo-conservation medium (2.1.2.2). Hybridoma clones (2.2.4.5)
were harvested directly from 24well plates at a concentration of 1-2x106 cells/ml. The
culture supernatant was removed completely and the cells were suspended in 1 ml of
ice cold cryo-conservation medium (2.1.2.2). The cryovials (Nunc) with 1 ml cell sus-
pension each were placed in a –80◦C freezer o/n and transferred to liquid nitrogen for
long-time storage.
Cryopreserved cells were thawed rapidly in a 37◦C water bath, transferred to 20 ml
prewarmed RPMI (20%) (2.1.2.2) and centrifuged (250 g/5min). TheDMSO-containing
supernatant was discarded and cells were seeded at high density in culture flasks
(25 cm2 and 75 cm2, respectively).
2.2.4.3 Determination of Cell Number
For determination of cell number 50 µl of the cell suspension was mixed with 10 ml
PBS. Cell number was determined using the Casy Cell Counter (Schaerfe System).
2.2.4.4 Immortilisation of B-cells
For preparation of the spleen cells, mice were euthanised with Isofluran (Abbott). The
spleen was dissected and the spleen cells were isolated by grinding the spleen through
a 100 µmnylon cell strainer (Falcon) using the plunger of a 5 ml syringe. The cells were
collected into 50ml of RPMI (SF) (2.1.2.1) and cell number was determined (2.2.4.3). An
equal amount of exponentially growing Sp2/mIL-6 mouse myeloma cells (2.1.10) was
harvested before spleen preparation. The spleen cells as well as the myeloma cells
were washed 2x with 30 ml RPMI (SF) by repetitive centrifugation (250 g/10 min/RT).
For the fusion procedure, 1x 108 - 2x 108 spleen cells were mixed in a 1:1 ratio with
myeloma cells. The cells were centrifuged (250 g/10 min/RT) and supernatant was re-
moved completely. After loosening the pellet by careful tapping, 1 ml of pre-warmed
PEG-1500 (Roche) was added within 1 min with soft shaking. The mixture was incu-
bated for 1 min in a 37◦C water bath and 1 ml of pre-warmed RPMI (SF) was added
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within 1 minute. After adding 3 ml of RPMI (SF) within 3 min and 10 ml within 3 min
the suspension was centrifuged (250 g/10 min/RT) and then incubated for 5 min in a
37◦C waterbath. The pellet was resuspended in 2 ml medium (RPMI (SF)) with 70%
(v/v) FCS. 38 ml HATmedium containing 10% BM condimed H1 (2.1.2.2) were added
and the cells were incubated at 37◦C, 5% CO2 for 4-10 days before single cell sorting
(2.2.5.9).
2.2.4.5 Propagation of Single Cells and mAb-Production
For generation ofmonoclonal hybridoma clones (2.2.4.4) single cells were sorted (2.2.5.9)
and subsequently cultivated in 96well plates. Growth and condition of the cells were
controlled microscopically every day. Clones reaching 70-90% of confluencewere trans-
ferred from 96well to 24well plates after one or two weeks. HATmediumwas replaced
stepwise with HT medium (50%, 100%) over a time period of 7 days and subsequent
this medium was replaced stepwise (50%, 100%) with RPMI(15%) within 7 days. The
Supernatant of clones was checked for production of monoclonal antibodies (2.2.5.6).
Producing clones were held in culture and expanded in 25 cm2 bottles (Greiner). After
reaching a cell density of approximately 106 cells/ml medium was changed to CD(C)
(2.1.2.2) for production of mAb and subsequent immunoprecipitation (2.2.5.10).
2.2.5 Protein Analysis
2.2.5.1 Quantification of Proteins
The concentration of proteins was determined by Bradford (BRADFORD, 1976). Coo-
massie brilliant blue G-250, used in Bradford tests, exists in three forms: cationic
(470-nm red), neutral (650-nm green), and anionic (595-nm blue). The binding of the
dye to protein causes a shift in the absorption maximum of the dye from 470 to 595 nm.
The increase in absorption at 595 nm was monitored. For Bradford assay 1-20 µl of
protein solution were transferred into 96-well-plates. BSA was also serially diluted
(0-7 µg) and used as standard. 200 µl of Bradford reagent were added to each dilution,
mixed with the proteins and incubated at RT for 10 min followed by the measurement
of OD595nm. For each dilution, measurements were performed in duplicate and the
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average was taken for the calculation of the protein concentration.
2.2.5.2 Two Dimensional Polyacrylamide Gel Electrophoresis (2D-PAGE)
2D-PAGE is widely used for analysis of the proteome by separating the proteins in
two dimensions. The first separation is carried out by isoelectric focussing (IEF) in the
Protean IEF cell (BioRad), where active rehydration of the sample and IEF were per-
formed automatically (GORG et al., 1999). The central part of this instrument are the
so-called strip holders (rehydration/equilibration/focusing trays), in which IPG strip
rehydration with sample solution under current and IEF are performed without fur-
ther handling after the strip is placed into the strip holder (2.2). Gel electrophoresis in
the first dimension was carried out using an immobilised pH gradient gel in the PRO-
TEAN IEF cell. IPG strips (BioRad) are made with buffering acrylamide derivatives
that contain either a free carboxylic acid or a tertiary amino group that is copolymer-
ized with acrylamide and bis-acrylamide. As such, the pH gradient is precast into the
gel and cannot shift during electrophoresis. The first dimension, IEF, was performed in
individual 7 cm IPG gel strips (BioRad). For this 15 µg of solubilised proteins (2.2.2.1)
were suspended in the rehydration buffer (2.1.2.1). Each sample contained 250 ng of
3 mouse proteins as internal standard. The rehydration and IEF was performed as
described in table 2.8.
Figure 2.2: Placing of sample and IPG strip in the strip holder. left picture: Sample loading in
rehydration/equilibration trays; right picture: Placing the IPG strip gel side down in the focusing tray.
After the IEF the IPG gel strip was equilibrated twice, for 15 min in 2x 10 ml equi-
libration buffer (2.1.2.1). During the first equilibration step 100 mg DTT was dissolved
in 10 ml equilibration buffer. In the second equilibration step, 250 mg iodoacetamide
was added to 10 ml of the equilibration buffer in order to remove excess of DTT (GORG
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et al., 1987). The equilibrated IPG gel strips were rinsed with deionised water for one
second and placed onto a piece of filter paper at one edge for a few minutes to drain
off excess equilibration buffer. Subsequently, strips were subjected to the second di-
mension electrophoresis.
Table 2.8: Guidelines for the PROTEAN IEF cell (BioRad)
Temperature 20◦C
Current max. 0.05 mA per strip
Sample volume 125 µl
Voltage Time
50 V 12 hours (Rehydration)
500 V 2 hour (Isoelectric focusing)
1000 V 2 hour (Isoelectric focusing)
8000 V 1 hours (Isoelectric focusing)
500 V hold (Isoelectric focusing)
The second dimension electrophoresis of isoelectric focused proteins was carried
out on a laboratory-made polyacrylamide gel (12%) in the presence of SDS as described
in GORG et al. (1988). The equilibrated IPG gel strips were placed on top of the SDS-
PAGE gel and overlayed with 2 ml of hot (75◦C) agarose solution. The SDS gel was
performed with a voltage setting of 120 V for 45 min and 180 V for 20 min. To estimate
the molecular mass of each spot, marker proteins (Prestained protein marker, NEB)
were placed on a filter strip next to the strip on the gel. Visualisation of proteins in 2D-
PAGEs was always carried out by using the PlusOne Silver Staining Kit (Amersham
Biosciences) following the manufacturers’ instructions.
2.2.5.3 SDS-PAA Gel Electrophoresis
Discontinuous SDS-polyacrylamide gel electrophoresis (LAEMMLI, 1970) was used for
separation of protein samples. Protein samples were separated on 12% SDS-PAGE
(2.1.2.1) or on 4-12% Bis-Tris NuPAGETM gels (Invitrogen) (2.1.2.1). For separation
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of protein samples under reducing conditions samples were denaturated in the pres-
ence of β-mercaptoethanol. Proteins were visualised by staining with 0.25% (w/v)
Coomassie brilliant blue (2.1.2.1) or Silver Staining (2.2.5.4). For estimation of molecu-
lar weights the SeeBlue marker(Invitrogen) was used.
2.2.5.4 Silver Staining of Proteins in PAA-Gels
The SDS-PAA gels for monitoring of the immunoprecipiation procedure (2.2.5.10) and
for subsequent MS-analysis (2.2.6) were silver stained as follows (SHEVCHENKO et al.,
1996). For each step and gel, 125 ml of buffer and water were used. Gels were incu-
bated in fixation-buffer (50% (v/v) methanol, 5% (v/v) acetic acid) for 20 min, washed
with 50% (v/v) methanol 10 min and dH2O 10 min and incubated with sensitising-
buffer (0.02% (w/v) sodium thiosulfate) for 1 min. Gels were washed 2x 1 min with
dH2O and incubated with 0.1% (w/v) silver nitrate for 20min at 4
◦C. After washing for
exact 2x 1 min with dH2O the gels were developed with 2% (w/v) sodium carbonate
containing 0.04% (v/v) formaldehyde. The staining reaction was stopped by shaking
the gels in 5% (v/v) acetic acid for 10 min. Developed gels were stored in 1% (v/v)
acetic acid at 4◦C.
2.2.5.5 Western Blot
Separated proteins (2.2.5.3)were electro-transferred from SDS-PAA gel to HybondTM -C
nitrocellulose membrane (Amersham Biosciences). 1-dimensional SDS-PAGES were
blotted using the XCell II Blot Module (Invitrogen) according to manufacturers’ pro-
tocol. Blotting of 2D-PAGE was performed with the BioRad Tank Blot System (2 h,
A=const, 300 mA). Membranes were blocked for 1 h at RT or at 4◦C o/n with 5%
(w/v) skimmed milk or 2% (w/v) BSA dissolved in PBST (2.1.2.1). Monoclonal an-
tibodies were detected with goat anti mouse AP-conjugated antibodies diluted 1:5000
(Table 2.2).
Proteins separated by 2D-PAGE (2.2.5.2) prior to blotting were incubated, after
blocking with 10% fish gelatine (w/v) in PBS, with 1012 phages (2.2.7). Attachment
of the phages was detected by addition of the primary anti-M13 antibody (1:5000)
and secondary GAMAP (IgG H+L) (1:2500) (Table 2.2). Proteins were visualised by in-
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cubation with Nitro Blue Tetrazolium chloride/5-bromo 4-chloroindol-3-yl phosphate
(NBT-BCIP, Pierce). Between all incubation steps membranes were washed three times
with PBST.
2.2.5.6 Enzyme-linked Immunosorbent Assay (ELISA)
Production of monoclonal antibodies by hybridoma (2.2.4.5) was verified by ELISA
(ENGVALL and PERLMAN, 1971). For this purpose 100-500 ng of unconjugated GAM
antibody (Serotec, 2.2) or 500 ng NP-cBSA (2.2.2.3) diluted in coating buffer (2.1.2.1)
was coated onto Microtitre plates (High-binding; Greiner Bio-One GmbH) o/n at 4◦C.
The plates were blocked with 3% (w/v) milk powder in PBST (250 µl/well) for 1 hour
at 37◦C. 100 µl of hybridoma supernatant was applied (1 h/37◦C) and bound mouse
antibody was detected with 100-500 ng/well of GAM antibody coupled to HRPO (2.2).
The ELISA was developed with 2-2’-azino-di-(3- ethylbenzthiazoline sulfonic acid)
(ABTS; preparation according to the manufacturers’ instructions) (Roche) substrate.
Resulting extinction wasmeasured at E405 nm using the microplate reader Spectra Max
340 (Molecular Devices).
For antibody titer determination from serum samples of immunised mice (2.2.3)
500 ng of cell lysate (2.2.2.1) or NP-cBSA (2.2.2.3) per well were coated onto Microtitre
plates (High-binding; Greiner Bio-One GmbH) o/n at 4◦C. The plates were blocked
with 3% milk powder in PBST (250 µl/well) o/n at 4◦C or 3 h at 37◦C. Dilutions of
mouse serum (1:2000-1:20000) were applied to the coated and blocked wells (2 h/RT).
Bound antibodies were detected with 100 ng/well of HRPO conjugated polyclonal
goat anti-mouse antibody (Sigma) (2.2). The ELISA was developed with tetramethyl-
benzidine (TMB) substrate or (Roche). Resulting extinction was measured at E450nm or
E405nm using the microplate reader Spectra Max 340 (Molecular Devices). Between all
incubation steps plates were washed three times with PBST.
2.2.5.7 Isotype Determination of Monoclonal Antibodies
The isotype determination was performed with the BD Pharmigen mouse Ig ELISA
isotyping kit according to the manufacturers’ instructions.
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2.2.5.8 Flow Cytometry
In general flow cytometry analysis enables the determination of optical and immuno-
fluorescence characteristics of a single cell. Inside a flow cytometer the cell suspension
passes the measurement cell as a laminar flow of single cells in isotonic shear fluid,
where they are intersected by monochromatic light. Measurement of light diffraction
allows determination of the physical properties of the cell, such as the size (represented
by forward scatter, FSC) and internal complexity (represented by side scatter, SSC).
Measurement of fluorescence activation further allows the quantification of the bound
fluorescent dye of immunofluorescence-labelled cells.
Here flow cytometry was used for the proof of the coating of monoclonal antibodies
to the surface of magnetic bead particles prior to immunoprecipitation (2.2.5.10). For
this purpose the coated beads (2.2.5.10) were blocked with 1 ml RPMI (15%) (2.1.2.2)
for 1 h at RT followed by subsequent incubation with 5 µg of GAMFITC (2.2) (30 min/
4◦C/in darkness). The fluorescent labelled beads were finally resuspended in 500 µl
FACS buffer (2.1.2.1), transferred into FACS tubes (Becton Dickinson Bioscience) and
subjected to flow cytometry measurement (FACScalibur, Becton Dickinson Bioscience).
The flow cytometry results were digitised, computer analysed using “Cell Quest” soft-
ware (Becton Dickinson Bioscience) and subsequently displayed as histograms descri-
bing the logarithmic distribution of the measured fluorescence intensity over the bead
population.
2.2.5.9 Fluorescent Activated Cell Sorting (FACS)
Cloning of hybridoma cells via single cell sorting was performed with a FACSVan-
tage SE with FACSDiVa option and FACSDiVa software (Becton Dickinson Bioscience).
Used fluorochromes are listed in table 2.9. After the fusion procedure (2.2.4.4) the cells
were cultured in HAT-medium (2.1.2.2) for 4 to 10 days until single hybridoma clones
had grown to a number of approximately 10-20 cells. At this time, all residual, un-
fused myeloma cells had died. The cells were harvested with a cell scraper, counted
and washed once with PBS (2.1.2.1). Approximately 1-2x 107 cells were mixed with
100-500 µl fluorescent labelled antigen mixture (2.2.2.4). To verify the presence of sur-
face immunoglobulins, 10-50 µl sheep anti mouse Ig antibody (2.2) coupled to FITC
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or PE were added and the mixture was incubated for 20 min at 4◦C in the dark with
careful shaking. The cells were washed twice with PBS and resuspended in 2 ml PBS.
Propidiumiodide (PI) was added immediately before the sorting procedure to a final
concentration of 2-5 µg/ml to discriminate between living and dead cells. Single Liv-
ing cells with expressing surface immunoglobulins and distinct EVOblue or Cy5 signal
were sorted into 96-well microtiter plates into 100 µl of their original culture super-
natant (steril-filtered) supplemented with 50% (v/v) fresh HAT medium. Plates were
cultured at 37◦C and 5% CO2.
Table 2.9: Excitation and emission wave lengths of used fluorochromes
Laser Excitation Fluorochrome Emission
Enterprise II 488 nm FITC 519 nm
PI 620 nm
PE 575 nm
Innova70 spectrum laser 633 nm EVOblueTM 30-NHS 670 nm
2.2.5.10 Immunoprecipitation
For the determination of the binding specificity of the mAb produced by hybridoma
(2.2.4.5), immunoprecipitation of antigen was performed. For this purpose magnetic
beads with covalently coupled rProtein G or rProteinA (Dynal) or GAM IgG antibody
(H+L) (Kisker) were used. 30 µl (Protein A/G) and 150 µl (GAM magnetic bead par-
ticles), respectively were incubated with 3-5 ml of hybridoma supernatant (2.2.4.5)
(2 h/RT/ shaking). To check sucessful binding of antibodies 3 µl samples of beads
were subjected to flow cytometry (2.2.5.8). Binding of antigen was carried out by
incubation with 0.5-1 mg fresh cell lysate of the appropriate cell line (2.2.2.1) which
previously was used for immunisation (2.2.3). Proteins were eluted by pH shift by
incubation with 28 µl of 0.1 M glycine buffer, pH 2.2 for 1 min and immediate neutral-
isation with 2 µl of 1.5 M Tris-HCl, pH 8.8. Between all incubation steps beads were
washed two times with PBS (2.1.2.1). Protein samples were further processed for mass
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Table 2.10: Excitation and emission wave lengths of used fluorochromes
Fluorochrome Excitation Emission
Alexa488 488 nm 603 nm
DRAQ5 633 nm 670 nm
spectrometrical analysis (2.2.6) or loaded on NuPAGETM gels and visualised via silver
staining (2.2.5.3, 2.2.5.4).
2.2.5.11 Molecular Imaging
To investigate the binding of the mAb HFL1-22 to its corresponding antigen immuno-
fluorescence was performed. For this purpose 1x105/well LS173T cells and 8*105/well
HFL1 cells (2.1.10) were seeded into black 96well plates (Greiner) and cultivated o/n at
37◦C and 5% CO2. After incubation the wells were blocked with RPMI (10%) (2.1.2.2)
(2 h/37◦C) and subsequently incubated with 200 µl HFL1-22 culture supernatant. De-
tection of the mAb was carried out by incubation with 2 µg/well GAMAlexa488 (2.2)
(1 h/37◦C). For staining of the nucleus cells were incubated with DRAQ5 (Biostatus
Ltd., USA). Between all incubation steps cells were carefully washed twice with 100 µl
PBS. The green and red fluorescence was measured fully automatically utilizing the
OPERA system (Evotec) with a 20x water immersion objective. The excitation and
emission maxima of the fluorochromes are listed in table 2.10. The evaluation and
overlay of the green and red fluorescence was carried out with Acapella 1.01 software.
2.2.6 Mass Spectrometry
Mass spectrometry is a very accurate method for protein analysis. It is highly sensitive
and small amounts down to 100 fmol are sufficient to identify an unknown protein in a
sample. Prior to analysis proteins are usually digested with trypsin, which cleaves be-
hind the basic amino acids lysine or arginine. The resulting peptides are transformed
into gas phase ions by either electrospray ionization (ESI) or matrix assisted laser
dissorption ionization (MALDI). The mass/charge ratio of positively charged ions is
2.2 Methods 46
measured via their transfer time through an electric field and from these ratios the
mass of each peptide is determined, leading to a characteristic peptide mass spectrum.
Single peptides species can be separated and bombarded with an inert gas, usually
argon, leading to a further fragmentation and a spectrum of their amino acids. These
MS/MS spectra are used for a correlative database search. Because from the MS/MS
data the sequence of the peptide is available, protein as well as DNA databases can be
included in the search for matching proteins.
2.2.6.1 Tryptic digest in Solution
Antibody/antigen complex eluates after antigen capturing (2.2.5.10) were digested by
incubation with 1 V of trypsin digestion buffer and 1 µg of porcine trypsin (Promega)
o/n at 37◦C. Tryptic digests of proteins were desalted with ZipTips (Millipore) accord-
ing to manufacturers’ instructions.
Trypsin Digestion Buffer
Ammoniumcarbonat 100 mM
CaCl2 13 mM
2.2.6.2 In-Gel-Digestion of Proteins
Silver stained (2.2.5.4) protein bands were excised out of SDS-PAGE after immunopre-
cipitation (2.2.5.10), cut into small pieces and washed with 150 µl ddH2O, 5 min. The
water was removed with a pipet and the gel blocks were incubated with 4 volumes of
acetonitril for 15 min. The acetonitril was removed, gel pieces were dried in a vacuum
concentrator (Eppendorf) and then covered with 10 mM DTT/0.1 M NH4HCO3 for
30 min, 56◦C to completely reduce disulfide bonds in the protein. Gel pieces were
shrinked again with acetonitril and then incubated with 55 mM iodoacetamide/0.1 M
NH4HCO3 for 20 min, RT, in the dark. Iodoacetamide was removed, the gel was
washed with 200 µl of 0.1 M NH4HCO3 for 15 min, shrinked with acetonitril and dried
in the concentrator. For tryptic digestion the gel pieces were rehydrated in the di-
gestion buffer containing 50 mM NH4HCO3 , 5 mM CaCl2 and 12.5 ng/µl of trypsin
at 4◦C for 30-45 min. The remaining supernatant was removed. 5-25 µl of digestion
buffer without trypsin were added to keep the gel wet during enzyme cleavage and
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samples were incubated o.n. at 37◦C. To extract the tryptic peptides 10-15 µl of 25 mM
NH4HCO3 were added, the mixture was incubated at 37
◦C for 15 min with shaking.
After removing all liquid 2x 1 volume of acetonitril was added. After 15 min, the su-
pernatant with the eluted peptides was collected and mixed with 40-50 µl of 5% (w/v)
formic acid. The extraction procedure was repeated, the combined extracts were dried
in the vacuum concentrator and desalted with ZipTips after resuspension in 10 µl 1%
(v/v) formic acid (Millipore).
2.2.6.3 Mass Spectrometry and Database Analysis
Mass spectrometry analyses were performed with a Micromass Electrospray Q-Tof-2
mass spectrometer andMasslynx 5.3 software. The instruments were set to a Capillary
voltage of 1.25 kV, a Cone voltage of 45 V, a Cone temperature of –80◦C and a MS col-
lision energy of 10 eV. From the obtained mass spectra, peptides were automatically
selected for further fragmentation. The resulting MS/MS data was transformed into
PKL files and transferred to the MASCOT search engine (PERKINS et al., 1999) accessi-
ble on http://www.matrix-science.com. The search was carried out within the NCBI
database. Allowedmodifications were oxidation of methionine and carboximethyl and
propionamide at cysteine residues resulting from the DTT and iodoacetamid treatment
and reaction with acrylamide during electrophoresis. The accuracy of the mass spec-
trometric data was set to 0.1 and only human matches were considered.
2.2.6.4 NP-capture and subsequent GCMS analysis
Another approach to characterise the antibody candidates was performed according
to the immunoprecipitation protocol (2.2.5.10). For this 500 µl of GAM magnetic bead
particles (Kisker Biotech) were incubated o/n with 5 ml of serumfree hybridoma su-
pernatant or CD(C) (2.1.2.2). After two washing steps with PBS approximate 60 ng of
NP (stock solution of 50 µg/ml in Ethanol) diluted in 100 µl PBS were added to the
beads for 2 h (4◦C). Supernatant was separated from beads. The beads were washed
1x with 100 µl PBS. NP was extracted from supernatants and washing fractions with
50 µl Hexan. 25 µl of the NP-containing hexan was subjected to GCMS analysis.
GC/MS analyses were carried out with a HP 5973 mass spectrometer (MSD) linked
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to a 6890 N with HP5 gas chromatograph (Hewlett Packard, Agilent Technologies).
A 25 m x 0.25 mm ID x 0.25 µm film fused 95% dimethylsilicone capillary column
(Fs-supreme5, CS Langerwehe, Germany) and the following conditions were applied
for GC analyses of the precursors: Temperature program was 85◦C for 5 min, then
10◦C/min gradient to 280◦C, which was held for 3 min. The injector temperature was
250◦C (splitless mode), and the interface temperature was 280◦C. Injection volume was
1 µl, and splitless time was 1 min. Carrier gas was helium with 1 ml/min. The electron
energy was 70 eV (EI). The mass spectrometer was operated in full-scan mode ranging
from m/z 50 to m/z 500 and scan time was 0.625 s.
2.2.7 Phage-Display Methods
To identify antibody-antigen pairs an scFv-library (2.1.8) was screened on cell lysates
of lung cancer cells (2.2.2.1) separated by 2D-PAGE (2.2.5.2). For enrichment of the
library one panning round was performed on lung cancer cells (2.1.10. For this pur-
pose phage particles were rescued from the scFv-library (2.1.8) by superinfection with
helper phage M13KO7 (CLACKSON et al., 1991). For isolation of phages exposing
antigen-specific antibodies following panning procedure was carried out. 1x 107 lung
cancer cells were incubated with 2% (w/v) milk powder in PBS (MPBS) (30 min/RT/
turntable). The same procedure was performed with 1012 phages. Then the phage so-
lution was added to the cells followed by further incubation (60 min/RT/turntable).
Phages that showed no or low affinity for the immobilised antigen were washed away
by PBS (2.1.2.1). The washing step was performed 30 times using a cell washer (Bax-
ter). Phages with affinity to the antigen were eluted from the cells by addition of 1 ml
freshly prepared 100 mM Triethylamine (8 min/RT/turntable) followed by neutralisa-
tion with 0.5 ml of 1 M Tris-HCl (pH 6.8). 9 ml of exponentially growing E. coli TG1
cells (OD620nm = 0.5-0.8) were infected with eluted phages and plated on 2x TY agar
plates containing 2% (w/v) glucose and 100 µg/ml ampicillin (2x TYGA-agar). The
plates were incubated overnight (o/n) at 37◦C. Cells were scraped off the agar plate
with a sterile spatula by adding 4 ml of 2x TY medium containing 15% (v/v) glycerol
and stored at -80◦C until further use.
Phages which showed binding to proteins separated by 2D-PAGE (2.2.5.2) and elec-
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trotransferred onto membrane detected by an anti-M13 antibody (2.2.5.5) were eluted
by cutting out the distinct spots and incubated with 20 µl Triethylamine (10 min/RT).
Subsequently, phages were neutralised with 20 µl of 1 M Tris-HCl (pH 6.8). 160 µl of
exponentially growing E. coli TG1 cells (OD620nm = 0.5-0.8) were infected with eluted
phages (1 h/37◦C) and plated on 2x TY agar plates containing 2% (w/v) glucose and
100 µg/ml ampicillin (2x TYGA-agar). The plates were incubated o/n at 37◦C. Clones
were analysed via PCR (2.2.1.1) and DNA digest (2.2.1.3).
2x TY-Medium (2x TY)
Pepton 1,6% (w/v)
Hefeextrakt 1,0% (w/v)
Natriumchlorid 0,5% (w/v)
Media supplement:
Agar 1.6% (w/v)
Chapter 3
Results
This thesis is divided into two chapters. The first chapter focusses on the generation of
a NP-specific antibody. In the second chapter establishment of a systemized approach
for the generation of new diagnostic tools for lung and pancreatic cancer is described.
3.1 Generation of a NP-specific Antibody (AGEESA)
Within the scope of this thesis a NP-specific antibody had to be generated. Nonylphe-
nol belongs to the endocrine disrupting substances. Amongst others it is found in
sewage water and sludge. The Aachener Graduate College for the Eliminination of
Endocrine Disrupting substances from waste water (AGEESA) focusses in a interdisci-
plinary project on different possibilities to remove NP and other endocrine disrupters
from the aquatic environment. To reach this goal for example microbial degradation as
well as membrane filtration methods were investigated. One further possibility for the
elimination of NP from wastewater could be a biofilter where antibodies which bind
specifically to this substance are immobilised on membranes or on the surface of algae
and plant cells. Figure 3.1 shows the scheme of this chapter.
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Characterisation of mAb- -
Figure 3.1: Scheme of the generation of a monoclonal antibody against NP.
3.1.1 Coupling of NP to cBSA
To elicit an immune response against the phenolic hapten NP it had to be conjugated
to an immunogenic carrier protein. As carrier cBSA was chosen and conjugation was
performed using the Imject R© SuperCarrier R© EDC System (Pierce). A generic scheme
of the EDC mediated coupling is shown in figure 3.2. 0.5 mg NP were subjected to
coupling (2.2.2.3) and the success of the coupling was proven by photometric measure-
ment of free NP in the wash fractions after purification of the conjugation product via
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PD10 columns. In preceeding control experiments NP alone showed a recovery rate
of 98.3% from the columns, when a washing solution including 30% (v/v) DMSO was
used. Measuring revealed that 62.89% of the NP (equivalent to 0.32 mg) had bound
to the carrier. 0.18 mg NP could be detected photometrically (E280nm) after extensive
washing in the wash fractions. The concentration of NP-cBSA was determined by
Bradford (2.2.5.1) to 454.75 ng/µl.
Figure 3.2: Scheme of EDC mediated hapten-cBSA-conjugation. The first step includes the reaction
of the carboxygroup of a peptide with EDC forming an activated peptide intermediate. In a second
reaction this intermediate reacts with an aminogroup of cBSA to form the conjugate.
3.1.2 Immunisation of Mice
Immunisation of three mice was carried out according to the immunisation scheme
shown in table 2.7. The used protocol is based on the fact, that initial injections of very
high amounts of a carrier protein alone lead to the development of a tolerisation of this
protein. These initial injections are followed by the injections of very small amounts
of antigen or by a standard immunisation. This procedure should prevent the produc-
tion of antibodies against the big carrier protein and boost the generation of antibodies
against the hapten. For unknown reasons one mouse (T2) died during the immuni-
sation and the final titre could not be determined. Further difficulties occurred in the
establishment of the ELISA set up (2.2.5.6) for determination of the titre. For example
preincubation of the serum and the detection antibody with 0.5% (w/v) BSA was re-
quired to minimise the unspecific binding to cBSA. Extensive set-up studies resulted
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in a lack of serum samples and only the endpoint of the titre curve after the last boost
could be determined. The titres of the two remaining mice in comparison to the serum
control (serum of a naïvemouse) and the negative control (secondary antibodies alone)
are shown in figure 3.3. It could be shown that the development of an antibody titre
specific for NP was provoked. Especially the mouse which was immunised according
to the tolerisation protocol with two initial injections of high amounts of cBSA (250 µg)
showed a significant signal which is nearly of double strength in comparison to the
mouse immunised according to a standard protocol which lacked these two initial in-
jections, which shows that the tolerisation led to a significant higher titre against NP
than the standard immunisation protocol. Due to this result, the T1 mouse was sacri-
ficed for spleen dissection and subsequent immortalisation of the B-cells by fusion with
myeloma cells.
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Figure 3.3: Endpoint measurement of specific Ab-titre after immunisation with NP. In order to
check the generation of antibodies after immunisation of mice an ELISA was performed (2.2.5.6). 500 ng
of coated NP-cBSA (2.2.2.3) was incubated with serum (1:1000) taken after the last immunisation boost.
Bound mouse antibody was detected with GAMHRPO (IgG/IgM) (2.2). For detection ABTS substrate
(Roche) was used and OD405 nm was measured after 60 min substrate incubation. SC = serum control,
T1 = serum of tolerisation 1, S = serum of standard, NC = negative control.
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3.1.3 Immortalisation of B-cells and Antigen-specific Single Cell
Sorting
1x108 spleen cells from mouse T1 were successfully fused with Sp2/mIL-6 myeloma
cells (2.2.4.4) right after preparation of the spleen. In addition, the same amount of
spleen cells were frozen and fused at a later time point under the same conditions as
before. Exact fusion efficiencies could not be determined, becausemicroscopic discrim-
ination between B-cell/myeloma fusions, other hybrids and unfused myeloma cells
was not possible. Approximately 10−4 clones as observed with standard PEG fusion
protocols (LANE, 1985) were obtained.
After the fusion of spleen-derived B-cells with immortal myeloma cells (2.2.4.4) the
cells were cultivated for 7 days under HAT (2.1.2.2) selection pressure. Until this time
point single clones had expanded to 10-20 cells. Instead of the classical limiting dilu-
tion steps, which is a very slow and labour intensive cloning method, the hybridoma
clones were processed using fluorescence activated cell sorting. This enables the dis-
crimination and individual sorting of single cells on the basis of light scattering and
autofluorescence criteria. Indeed, due to limitations of the machine only 10% of the
selected cells are sorted into the wells while the other 90% are lost. Therefore prolifer-
ation to 10-20 cells of each hybridoma clone is required, in order not to loose diversity
during the sorting procedure.
Two different sorting approaches were performed. In a first approach only living
cells were single cell sorted (2.2.5.9). To obtain maximal growth rate of single cells the
hybridoma clones were sorted into conditioned HAT medium mixed 1:1 with fresh
HAT medium into 96well plates. Figure 3.4 shows the dot plots of the sorting.
Plot A displays the total cell population inclusive dead cells, B-cells and other non-
hybridoma cells depending on their granularity (SSC-H) and their size (FSC-H). In gate
P1 the hybridoma cells were pre-defined according to their size and granularity. Un-
fused B-cells, apoptotic cells and cell debris were excluded because they were smaller
or showed a higher granularity. Most of the cells within the gate should be living cells .
To increase the reliability of the sorting, Propidium Iodide (PI) was added to the cells.
PI is able to pass the membrane of dead but not of living cells and emits fluorescence
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Figure 3.4: FACS analysis of NP hybridoma with PI. In order to obtain living monoclonal hybridoma
cells, the hybridoma cells after fusion (2.2.4.4) were incubated with PI. Afterwards the cells were sub-
jected into FACS analysis with subsequent single cell sorting of PI negative cells (2.2.5.9). Plot A: the
cell size (FSC-H) is plotted against the granularity (SSC-H). Plot B: the PI signal indicating the viability
of the cells is plotted against the FITC signal (no FITC used). Plot C: EVOblue signal is plotted against
the PI signal. Gate P1: Pre-defined hybridoma cells according size and granularity. Fused cells were
incubated with PI (2 µg/ml) immediately before single living cells (gate P3) were sorted.
at a wavelength of 620 nm when it is incorporated into the DNA double helix. The PI
signal is displayed in plot B. The population of P1 (red marked cells) corresponds with
the PI negative, living cells, determined by gate P3. An additional plot (C) displays
the fluorescence of EVOblue (Evo) against PI. EVOblue is a fluorescent dye and NP
coupled EVOblue (2.2.2.4) was used as sorting criteria in a second antigen-specific ap-
proach (see below). In plot C only cells which matched P1 and P3 are displayed. This
plot shows only a weak unspecific signal of EVOblue-fluorescence (gate P2). It is im-
portant to note that apoptotic cells emit auto-fluorescence that is detected in the same
channel as the EVOblue signal. 470 cells were sorted out of gate P3. Only 35 clones
survived and grew which translates to less than 10% survival rate and not satisfying in
comparison to other single cell sorting performed, reaching growth rates of up to 40%
(described below).
In a second approach only antigen-specific cells were sorted. For this purpose the
cells were additionally incubated with EVOblue conjugated to NP (2.2.2.4). In figure
3.5, the dot plots of this sorting are shown. Because the composition of the culture was
the same as in the first sorting approach (3.4) plot A and B look alike. In contrast to this,
in plot C an additional cell population is visible in gate P2. This cell population shows
a clear EVOblue signal. EVOblue labelledNP has probably bound tomembrane bound
surface Ig on living hybridoma cells. 144 cells were sorted from this population into
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complete conditioned HATmedium. 52 clones survived and grew, which is equivalent
to a survival rate of 36%.
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Figure 3.5: FACS analysis of NP hybridoma with PI and EVOblue stained NP. In order to obtain living
and NP-specific monoclonal hybridoma cells, the hybridoma cells after fusion (2.2.4.4) were incubated
with PI and EVOblue labelled NP (2.2.2.4). Afterwards the cells were subjected into FACS analysis with
subsequent single cell sorting of EVOblue positive and PI negative cells (2.2.5.9). Plot A: size of the
cells (FSC-H) is plotted against the granularity (SSC-H). Plot B: the PI signal indicating the viability of
the cells is plotted against the FITC signal (no FITC used). Plot C: EVOblue signal is plotted against
the PI signal. Gate P1: Pre-defined hybridoma cells according size and granularity. Gate P3: Living
hybridoma cells. 1*107 cells were incubated with 100 µl of EVOstained NP. PI (2 µg/ml) was added
immediately before single living and EVOblue positive cells (gate P2) were sorted.
3.1.4 Characterisation of mAbs against NP
In total 87 hybridoma clones were obtained. The supernatants of these clones were
tested in ELISA (2.2.5.6) for the production of NP-specific antibodies. To verify the
binding of NP an immunoprecipitation with subsequent GCMS (2.2.6.4) analysis was
also performed.
3.1.4.1 ELISA
ELISAwas carried out as described in 2.2.5.6. The supernatants of 87 hybridoma clones
were tested (2.2.5.6). Figure 3.6 shows the results of 10 clones which showed binding
to NP (data of the remaining 77 clones not shown). Three clones of the first sorting
approach and 8 clones of the second sorting approach showed a significant signal on
NP-cBSA but not on cBSA alone (results of cBSA control not shown). A signal was
judged as significant if it was three times the signal of the negative control and if the
signal was higher than E405nm = 0.2. The horizontal orange line marks the value of the
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triple value of the negative control. Unfortunately clone 28, 30, 41, 68 and 93 stopped
producing antibodies, while clone 54 and 68 stopped growing just before stocks were
build up.
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Figure 3.6: Antigen specific ELISA on NP-cBSA using hybridoma supernatant of 10 clones. In
order to identify clones which produce NP-specific antibodies an ELISA was performed (2.2.5.6). 500
ng of coated NP-cBSA was incubated with 100 µl of hybridoma supernatant. Bound mouse antibody
was detected with GAMHRPO (IgG/IgM). For detection ABTS substrate (Roche) was used and OD405 nm
was measured after 60 min substrate incubation. NC = negative control; orange horizontal line = 3x NC
3.1.4.2 Production of mAb NP78
For longerm storage of hybridomas cryo-backups were made (2.2.4.2). Further charac-
terisation was focussed on the mAb 78. For the production of the antibody on 10
ml scale the clone NP78 was transferred to 25 cm2 culture flasks and cultivated with
serumfree hybridoma medium CD (C). Supernatant was analysed by ELISA (2.2.5.6)
for production of monoclonal antibodies (data not shown). Subsequent analysis was
performed by SDS-PAGE (3.7). The antibody heavy chain with 62 kDa and the anti-
body light chain (28 kDa) are clearly detectable. Additionally, the isotype of mAb 78
was determined as IgM (2.2.5.7), which correlates with the observations regarding the
size of the heavy chain made in the SDS-PAGE. Due to the following affinity capturing
steps with GAM beads no further purification was required.
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Figure 3.7: SDS-PAGE of serumfree hybridoma culture supernatant under reducing conditions. In
order to check the production and integrity of mAb NP78 SDS-PAGE analysis was performed (2.2.5.3).
Hybridoma supernatant (15 µl) was loaded onto a NuPAGETM gel in the MES buffer system under
reducing conditions. Proteins were visualised by staining with 0.25% (w/v) Coomassie brilliant blue
(2.1.2.1). M: Prestained protein marker SeeBlue (Invitrogen); PC = 2 µg of mAb CA19.9; Lane 3:
Hybridoma supernatant of mAb NP78.
3.1.4.3 Characterisation of mAb NP78
The binding of the mAb NP78 was analysed according to the immunoprecipitation
protocol (2.2.6.4). As a control of the coating of the antibody to the GAM beads a
FACS analysis (2.2.5.8) was performed. Successful binding of the NP78 antibody from
culture supernatant could be shown. No antibody could be detected on the beads
coated with fresh CD(C) (figure 3.8). The FITC signal of the whole bead population
(Plot B) showed two peaks. This originated from different bead populations. The
beads form aggragates which results in a second peak.
The beads coated with NP78-mAb were incubated with 60 ng NP. The NP concen-
tration in the supernatant and washing fraction after incubation was extracted with
Hexan. TheNP concentration of the extraction fractionwas analysed byGCMS (2.2.6.4).
The integrated area under the NP peaks in GCMS analysis is presented in table 3.1. The
integral of a peak is defined as the area under the peak and therefore stands in direct
relationship to the NP concentration detected. Presented is the manual determined
integral (Man Int) as well as the automatic determined integral (Aut Int). Although,
the actual amount of NP could not be determined, due to difficulties with the extrac-
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Figure 3.8: FACS analysis of GAM beads coated with antibody. The successful coating of mAb
NP78 to GAM beads was proven by FACS analysis (2.2.5.8). Plot A: size of the beads (FSC-H) is plotted
against the granularity (SSC-H). Plot B: the FITC signal of the whole bead population is plotted against
bead counts. Plot C: the FITC signal of the beads in Gate 1 (G1) is plotted against bead counts. 3 µl
of beads after incubation with medium and supernatant (2.2.6.4) were incubated with 10 µg SAMFITC .
10,000 beads were counted. Blue curve: beads coated with CD(C) (negative control); black and red
curve, respectively: beads coated with NP78 supernatant.
tion method in such a small volume (50 µl), these results confirm the specificity of the
NP78 antibody for NP. The NP concentration in 25 µl of hexan (extraction fraction) af-
ter identical treatment of the control and NP78 samples differs significantly in the two
supernatant samples. The concentration of NP in the supernatant of the beads coated
with NP78 is only 53% of the amount in the control supernatant. This indicates a sig-
nificant NP binding to the antibodies coupled to the surface of the beads. As estimated
the amount of NP in the wash fractions is approximately the same.
Table 3.1: Integrals of NP-Peaks in GCMS analysis
Fraction Man Int Aut Int Average Value
Supernatant Control 4982 5088 5035
Supernatant NP78 2589 2780 2684.5
Wash Fraction Control 2550 3133 2841.5
Wash Fraction NP78 2652 3341 2996.5
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3.2 Systemised Approach for High-Throughput Gener-
ation of Antibodies and Identification of the Corre-
sponding Antigens
The second part of this thesis focusses on the generation of antibodies recognising hu-
man proteins in particular proteins of the lung and pancreatic proteome. The goal was
to develop an approach which allows the generation of antibodies and identification of
the corresponding antigens in a high throughput fashion amenable to industrialisation
in the long run. The aim would be to develop novel diagnostic tools based on a dis-
ease characteristic protein signature. Two approaches were investigated. The first uses
the phage display and 2D-PAGE technologies. A scheme of this approach is displayed
in figure 3.9. The second approach utilises the hybridoma technology and automated
single cell sorting.
Sample Preparation-
2-dimensional Electrophoresis/
Western Blot
-
-
Selection by Phage Display- - -
Phage Recovery-
Characterisation of Phages- -
Spot Picking from 2D-PAGE- - -
Antigen Identification-
Figure 3.9: Schematic presentation of the phage display approach.
3.2 Systemised Approach for High-Throughput Generation of Antibodies and
Identification of the Corresponding Antigens 61
3.2.1 Phage Display Approach
3.2.1.1 Unselected Naïve scFv-Phagemid-Library
To identify antibody-antigen pairs a scFv-library (2.1.8) ought to be screened on cell
lysates of lung cancer cells (2.2.2.1) separated by 2D-PAGE (2.2.5.2). 15 µg of H1373
cell lysate were separated in the first dimension according to the IP of the proteins on
IGP-strips (pH 3-10) in duplicate. Second dimension of separation was performed on
12% laboratory-made SDS gels. Proteins on one gel were visualised by silver staining
(2.2.5.4), the second gel was subjected to Western Blot (2.2.5.5). Proteins transferred
to nitrocellulose membrane were incubated with 1012 phages from the phage library.
Unbound phages were removed by washing and bound phages were detected by in-
cubation with secondary antibodies as described in (2.2.5.5). Up to 600 distinct protein
spots are visible by eye in a wide range of concentration. Sizes of the different proteins
vary between 6 kDa and 90 kDa. Distinct spots are detectable between a pH of 3.5 and
10. Detection of proteins inWestern Blot with specifical binding phages resulted in two
distinct spots (results not shown). One round of selection was carried out on the cell
surface to enrich the naïve library for binder to lung proteins.
Figure 3.10: 2D-PAGE of H1373 cell lysate. The proteins in the lysate of H1373 cells (2.1.10, 2.2.2.1)
was analysed by 2D-PAGE. 15 µg of H1373 cell lysate (2.2.2.1) were separated on IPG-strips pH 3-
10 followed by 12% laboratory-made SDS-PAGE (2.2.5.2). Proteins were detected by silver staining
(2.2.5.4).
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3.2.1.2 Selection of Naïve scFv-Phagemid-Library on H526 cells
Selection was performed on H526 cells as described (2.2.7). Output of phages after one
round of selection was determined to be 1.9x 107. Eight bacteria clones were subjected
to PCR (2.2.1.1) to verify the selection of phages containing scFv Ab fragments. The
PCRs are shown in figure 3.11 A. Seven out of 8 clones had an insert of the expected size
of around 900 bp. The PCR products were further subjected to a DNA-digest (2.2.1.3)
with HaeIII to investigate diversity of the antibody inserts. (3.11 B). After digest five
different band pattern appeared, which indicates that one round of selection on surface
proteins already showed an enrichment.
A B
Figure 3.11: Agarose electrophoresis of PCR-product and fingerprint of selected scFv phagemid
DNA. PCR was performed as described (2.2.1.1). 5 µl of the PCR-reaction were applied onto a 1.2%
TAE agarose gel (2.2.1.2). 27 µl of PCR reaction were subjected into enzyme digest (2.2.1.3) and
digestion products were separated by 2% TAE agarose gel (2.2.1.2) Lanes 1 = 2log-ladder (500ng); A
lanes 2-9 = scFv PCR-products clone 1-8; B lanes 2-8 = digestion products clone 1-7
After one round of selection the rescued phages were used for binding to lung pro-
teins separated by 2D-PAGE of the cell lysate followed by subsequent Western Blot.
This time 15 µg of H526 cell lysate (2.2.2.1) were separated in the first dimension ac-
cording to the IP of the proteins on IGP-strips pH 3-10 in duplicate. The second di-
mension of separation was performed on 12% laboratory-made SDS gels. Proteins on
one gel were visualised by silver-staining (2.2.5.2), the second gel was subjected to
Western Blot (2.2.5.5). Proteins transferred to nitrocellulose membrane were incubated
with 1012 phages from the enriched phage library. Unbound phages were removed by
washing and bound phages were detected by incubation with secondary antibodies
as described in (2.2.5.5). Figure 3.12 shows the silver stained gel. Up to 400 distinct
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spots are visible by eye in a wide range of concentration. Sizes of the different pro-
teins vary between 6 kDa and 90 kDa. Distinct spots were detectable between a pH
of 3.5 and 10. Detection of proteins in Western Blot with specifically bound phages
resulted in 19 distinct spots, which were cut out directly after development of the blots
(results not shown). Phages could be eluted from the spots, but we were not able to
elute exclusively the specifically binding phages, due to a strong background. Finger-
print analysis of clones showed various band pattern resulting from unspecific phages
which bound to the membrane next to the spots or different antibody specificities for
several epitopes. Specificity had to be investigated in ELISA on purified protein or
on Western blot of 2D-PAGE with each single phage clone, which was not feasible.
Further, due to the amount of visible spots it had been impossible to identify the cor-
responding spots on the silver stained duplicate without appropriate computer soft-
ware and colony picker. Furthermore automation equipment is needed to isolate the
corresponding antigen from the nitrocellulose after elution of the phages.
Figure 3.12: 2D-PAGE of H526 cell lysate. The proteins in the lysate of H526 cells (2.1.10, 2.2.2.1)
was analysed by 2D-PAGE. 5 µg of H526 cell lysate (2.2.2.1) were separated on IPG-strips (pH 3-
10) followed by 12% laboratory-made SDS-PAGE (2.2.5.2). Proteins were detected by silver staining
(2.2.5.4).
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3.2.2 Hybridoma Approach
As the phage display approach was not easily adaptable to the identification of anti-
body-antigen-pairs an alternative was established using the hybridoma technology for
the generation of new monoclonal antibodies. The first step for the generation of
monoclonal antibodies was the immunisation of mice with appropriate antigen. Af-
ter successful immunisation, spleen-derived B-cells were immortilised by fusion with
myeloma cells and the resulting hybridoma clones were sorted as single cells using an
automated cell sorter. Antibody producing clones were cultured and antibodies were
used to immunoprecipitate the corresponding antigen which was identified by mass
spectrometry. Figure 3.13 shows the scheme of this approach.
Sample Preparation-
Immunisation of Mice- -
Generation of Hybridoma Cells- - -
Pre-selection and Cloning- -
Propagation of Single Cells- - -
Antigen Identification-
Characterisation of Antibody-
Antigen-Pair
- -
Figure 3.13: Schematic presentation of the hybridoma approach.
3.2 Systemised Approach for High-Throughput Generation of Antibodies and
Identification of the Corresponding Antigens 65
3.2.3 Immunisation of Mice
Two mice each were immunised with whole cells, cell lysate or tissue lysate accord-
ing to the immunisation scheme shown in table 2.5 and 2.6. The success of the im-
munisation was measured by ELISA (figure 3.14). For the immunisation with lung
cells and lung cell lysate the titre was determined at a serum dilution of 1:1000 us-
ing a GAMHRPO(IgG/IgM) (table 2.2). In case of the pancreatitis tissue lysate the IgG
and IgM titre were determined separately using GAMHRPO(IgG) and GAMHRPO(IgM),
respectively. The serum dilution was 1:500. Further information on the immunisation
with pancreatic tissue lysate has been described (F.Kampmeier, diploma thesis, RWTH,
BioVII, 2005).
Graphs A-D show the IgM and IgG immune responses. The antibody titres of all
four mice develop as expected. After a short lag phase the titre raises in an almost
exponential way until the point where the titre development levels out and remains
at the maximum. In case of the immunisations with HFL1 the maxima extinctions
are about 2-3.2, while the titre of the mice immunised with H1373 material raises to a
much lower extinction of 0.8-1.5. The response to the injections of tissue lysate (E) is
very weak at the beginning. After 3 boosts the IgG titre raises to an extinction of 0.6,
while the IgM amount declines towards 0.
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Figure 3.14: Development of polyclonal antibody titres during immunisation. In order to check
the generation of antibodies after immunisation of mice an ELISA was performed (2.2.5.6). 500-1000
ng of coated antigen was incubated with the sera (1:1000 (A-D); 1:500 (E)) from different time points
during the immunisation. Bound antibody was detected with GAM antibodies (GAMHRPO (IgG/IgM) (A-
D), GAMHRPO (IgG) and GAMHRPO (IgM) (E)). For detection ABTS substrate (Roche) was used and
OD405 nm was measured after 60 min substrate incubation. Negative controls were already subtracted.
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3.2.4 Optimisation of Spleen Cell Preparation
In the beginning different methods for the preparation of spleen derived B-cells were
tested with the aim to maximise the yield as well as to determine the fastest and the
most gentle method. The standard preparation includes the mazerisation of the spleen
through a sterile, coarse meshed sieve. This method accumulates all kinds of differ-
ent cells (B-cells, T-cells etc.) as well as tissue debris which are used for the fusion
with myeloma cells. To circumvent the contamination with debris a density gradient
centrifugation using Ficol was carried out prior to the fusion procedure. However,
the outcome (Table 3.2) was not satisfying. Additionally the cells were stressed by the
density gradient centrifugation and therefore the fusion was not optimal. Furthermore
the perfusion of the spleen with medium was tested. This lead to an increase in lym-
phocytes (Table 3.2) but this method is very slow and labour intensive. The highest
number of isolated lymphocytes was obtained by passing the spleen through a cell
sieve (BD Biosciences) (Table 3.2) which was also the most rapid method. The tissue
was not destroyed and only cells were isolated for the fusion.
Table 3.2: Number of viable lymphocytes isolated from spleen
Ficoll Perfusion Cell sieve
3*106 lymphocytes 7*107 lymphocytes 2*108 lymphocytes
3.2.5 Optimisation of Single Cell Culturing
The standard cloning method for hybridoma cells is the limiting dilution. But this pro-
cedure is very labour intensive and time consuming. The FACS provides the possibility
of a one step cloning for the generation of monoclonal hybridoma cell lines. Addition-
ally, the cloning by FACS is very fast and applicable to automatisation. Depending
on the cell density of the starting cell solution 100 clones can be obtained in 3-5 min-
utes. However, the subsequent single cell sorting (2.2.5.9) and subsequent single cell
culturing (2.2.4.4) requires special culture conditions. Different culturing conditions re-
garding the medium were tested. The growth rates are shown in table 3.3. The growth
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in a mixture of conditioned and fresh HAT medium with additional BM condimed
(Roche) seemed to provide the best conditions for the cultivation of single hybridoma
cells. Therefore all subsequent single cell sortings were carried out in this medium.
Table 3.3: Growth rates of single hybridoma clones depending on culture medium
RPMI (10%)
(2.1.2.2)
RPMI (10%) + BM condimed
(2.1.2.2)
conditioned HAT : fresh HAT
(1:1) + BM condimed (2.1.2.2)
0% 0-5% 30-40%
3.2.6 Immortalisation of Murine B-cells and Antigen Specific Sin-
gle Cell Sorting
Different fusion techniques were performed to optimise the protocol and culture con-
ditions (3.2.4, 3.2.5). For this purpose mouse 1 and 2 of the HFL1-cell immunisation,
mouse 1 of the HFL1-cell lysate immunisation as well as mouse 1 of the H1373-cell and
the H1373 cell lysate immunisation were sacrificed. The hybridoma if existent were
not yet further investigated.
The spleen cells from mouse 2, which was immunised with H1373 cells (2.1.10) (re-
sulting hybridoma called H1373I), mouse 2 immunised with HFL1 cell lysate (2.2.2.1)
(resulting hybridoma called HFL1), the spleen cells of mouse 2 immunised with H1373
cell lysate (2.2.2.1) (resulting hybridoma called H1373-GFP) and the splenic cells of
mouse PTL2 immunised with pancreatitis tissue lysate (resulting hybridoma called
PTL2) (diploma thesis F. Kampmeier, RWTH Aachen, BioVII, 2005) were successfully
fused to Sp2/mIL-6 myeloma cells, although the exact fusion efficiencies could not
be determined, because microscopic discrimination between B-cell/myeloma fusions,
other hybrids and unfused myeloma cells was not possible. It may range around 10−4
as observed with standard PEG fusion protocols (LANE, 1985).
3.2 Systemised Approach for High-Throughput Generation of Antibodies and
Identification of the Corresponding Antigens 69
3.2.6.1 H1373I
Afirst single cell sorting approach using labelled lung cell lysate (2.2.5.9) of the H1373I-
hybridoma was performed 14 days after the fusion, but due to residual detergent
present in the lysate, cells were destroyed. Therefore, the remaining hybridoma were
cultured for an additional 7 days before a second sorting approach was carried out.
Hybridoma cells were incubated with EVOblue stained cell lysate (2.2.2.4) and SAMPE
(2.2). EVOblue or double fluorescent living cells were sorted. The dot plots of the sort-
ing are shown in figure 3.15. Plot A displays the whole cell population depending
on size (FSC-A) and granularity (SSC-A). The population of hybridoma based on size
and granularity is defined by gate P1. Unfused B-cells, apoptotic cells and cell debris
were excluded because they were smaller or show a higher granularity. Exclusively
cells matching the characteristics of the gate are displayed in plot B, depending on
their fluorescence caused by binding of the PE-labelled anti-Ig antibody and EVOblue
stained cell lysate to surface bound Igs. Hybridoma cells showing an EVOblue fluores-
cence, which indicates the binding to lysate proteins, are shown in quadrant Q4, while
double fluorescent cells, which also show a PE signal, which indicates the expression
of surface Igs, are shown in Q2. Cells of both quadrants were sorted into five 96well
plates with sterile filtered original culture medium supplemented with fresh medium
and BM condimed (3.2.4) to achieve maximum single cell growth. From the 480 cells
sorted 150 stable clones could be established, which corresponds to a survival rate of
31%.
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Figure 3.15: FACS analysis of H1373I hybridoma with EVOblue stained cell lysate and SAMPE . In
order to obtain living and cell lysate-specific monoclonal hybridoma cells, the hybridoma cells after fusion
(2.2.4.4) were incubated with EVOblue labelled cell lysate (2.2.2.4) and SAMPE (2.2) and afterwards
were subjected into FACS analysis with subsequent single cell sorting of EVOblue positive and PE
positive cells (2.2.5.9). Plot A: size of the cells (FSC-A) is plotted against the granularity (SSC-A). Plot
B: the EVOblue signal indicating antigen bound by membrane standing antibodies is plotted against the
PE signal indicating presentation of Igs on the cell surface. Cells of the H1373I fusion were incubated
with 200 µl cell lysate (2.2.2.4) and 50 µg SAMPE (2.2). Gate P1 marks the typical population of living
hybridoma depending on size and granularity. Cells marked by Gate P1 are display in plot B. Cells which
lie in quadrant Q2 (Ig presenting cells binding EVOblue stained proteins) and Q4 (cells binding EVOblue
stained proteins) were sorted into 96well plates.
3.2.6.2 HFL1
The HFL1 hybridoma culture was single cell sorted (2.2.5.9) 8 days after fusion. Two
sorting approaches were carried out. One approach was used to sort only living cells
without analysis of further sorting criteria. The dot plots of this sorting are shown in
figure 3.16. Plot A displays the total cell population including dead cells, B-cells and
other non-hybridoma cells depending on their granularity (SSC-A) and their size (FSC-
A). In Gate P1 the hybridoma cells were defined according to their size and granu-
larity. Unfused B-cells, apoptotic cells and cell debris were excluded because they were
smaller or show a higher granularity. Most of the cells within the gate should be living
cells. To increase the reliability of the sorting, Propidium Iodide (PI) was added to
the cells. PI is able to pass the membrane of dead but not of living cells and emits
fluorescence at a wavelength of 620 nm when it is incorporated into the DNA double
helix. The PI signal is displayed in plot B. The population of P1 (red marked cells)
corresponds overall with the PI negative, living cells, determined by gate P2 (green
and red cells). The high number of PI negative, but very small cells (green cells) may
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represent the residual unfused B-cells.
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Figure 3.16: FACS analysis of HFL1 hybridoma with PI. In order to obtain living and cell lysate-
specific monoclonal hybridoma cells, the hybridoma cells after fusion (2.2.4.4) were incubated with PI
and afterwards subjected into FACS analysis with subsequent single cell sorting of PI negative cells
(2.2.5.9). Plot A: size of the cells (FSC-A) is plotted against the granularity (SSC-A). Plot B: the FITC
signal (no FITC labelled antibody used) is plotted against the PI signal, indicating dead cells. PI (2 µg/ml)
was added immediately before single living cells (red cells in gate P2) were sorted. Gate P1 (red cells)
marks the typical population of living hybridoma depending on size and granularity. Red cells also
matching in gate P2 were single cell sorted.
In a second approach only antigen-specific cells were sorted. For this purpose the
cells were additionally incubated with Cy5 stained cell lysate (2.2.2.4). The dot plots of
this sorting are shown in figure 3.17. Plot A displays again the whole population de-
pending on the size (FSC-A) and granularity (SSC-A). Gate P1 defines the hybridoma
population (red cells). Only cells matching the requirements in size and granularity
of P1 are displayed in plot B. Obviously a high number of the hybridoma cells are
apoptotic indicated by the PI positive cells. Nevertheless, PI negative cells which were
stained by Cy5 labelled cell lysate are defined by gate P2 and were subsequently sorted
into 96well plates with sterile filtered original culture medium supplemented with
fresh medium and BM condimed (3.2.4). Overall 384 cells were sorted into the con-
ditioned medium. 150 clones could be established which is equivalent to an efficiency
of 40%.
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Figure 3.17: FACS analysis of HFL1 hybridoma with Cy5 labelled cell lysate and PI. In order to ob-
tain living and cell lysate-specific monoclonal hybridoma cells, the hybridoma cells after fusion (2.2.4.4)
were incubated with Cy5 labelled cell lysate (2.2.2.4) and PI and afterwards were subjected into FACS
analysis with subsequent single cell sorting of Cy5 positive and PI negative cells (2.2.5.9). Plot A: size
of the cells (FSC-A) is plotted against the granularity (SSC-A). Plot B: the PI signal, indicating dead cells
is plotted against the Cy5 signal indicating binding of stained cell lysate. Cells of the HFL1 fusion were
incubated with 200 µl cell lysate (2.2.2.4). PI (2 µg/ml) was added immediately before single living cells
(gate P2) were sorted. Gate P1 (red cells) marks the typical population of living hybridoma depending
on size and granularity. Red cells also matching in gate P2 were single cell sorted.
3.2.6.3 Cell Sorting Controls
Two essential controls are shown in figure 3.18 and figure 3.19. In figure 3.18 the hy-
bridoma cells were incubated with EVOblue stained BSA (2.2.2.4). Plot A displays the
culture regarding size and granularity as before. In plot B only cells defined by gate P1
are displayed depending on their PI signal. In plot C the EVO signal of the living cells
(P2) is shown. The signal in the EVOblue channel of the BSA negative control is around
102, that means about one order of magnitude higher than the cells without EVO in-
cubation (data not shown). Thus, a signal in this range can be regarded as unspecific
background.
The second essential control is shown in figure 3.19. The hybridoma cell line Bo9
produces an antibody against the allergen Phl p Vb from common timmothy grass
pollen. These hybridoma cells were used to investigate the unspecific binding of the
lung cancer cell lysate to hybridoma cells. For this purpose 1*107 cells were incubated
with EVOblue stained H1373 cell lysate (2.2.2.4) and subsequently analysed by flow
cytometry. In comparison to the control with BSA the EVO signal increased slightly
revealing unspecific binding. However, it is important to note that apoptotic cells emit
auto-fluorescence that is detected in the same channel as the EVOblue signal.
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Figure 3.18: FACS analysis of hybridoma with EVOblue labelled BSA and PI. In order to analyse
unspecific binding of EVOblue to hybridoma, hybridoma cells after fusion (2.2.4.4) were incubated with
EVOblue labelled BSA (2.2.2.4) and PI. These cells were subjected into FACS analysis (2.2.5.8). Plot
A: size of the cells (FSC-A) is plotted against the granularity (SSC-A). Plot B: the PI signal indicating the
viability of the cells is plotted against the FITC signal (no FITC used). Plot C: EVOblue signal is plotted
against the PI signal. 1*107 cells from a H1373 fusion were incubated with 50 µl EVOblue labelled
BSA. PI (2 µg/ml) was added immediately before FACS analysis. Gate P1 (red/green cells) marks the
typical population of living hybridoma depending on size and granularity. Gate P2 marks the pre-defined
hybridoma cells (P1) as PI negative and therefore as living cells (green cells). Cells marked by gate P2
are displayed in plot C by their PI signal against the EVOblue fluorescence of BSA.
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Figure 3.19: FACS analysis of Bo9-hybridoma with EVOblue labelled cell lysate of H1373 cells
and PI. In order to analyse unspecific binding of EVOblue labelled cell lysate to hybridoma, hybridoma
cells after fusion (2.2.4.4) were incubated with EVOblue labelled H1373 cell lysate (2.2.2.4) and PI.
These cells were subjected into FACS analysis (2.2.5.8). Plot A: size of the cells (FSC-A) is plotted
against the granularity (SSC-A). Plot B: the PI signal indicating the viability of the cells is plotted against
the FITC signal (no FITC used). Plot C: EVOblue signal is plotted against the FITC signal (no FITC
used). 1*107 Bo9 hybridoma cells were incubated with 200 µl EVOblue labelled H1373 cell lysate
(2.2.2.4). PI (2 µg/ml) was added immediately before FACS analysis. Gate P1 (green cells) marks the
typical population of living hybridoma depending on size and granularity. Gate P2 marks the pre-defined
hybridoma cells (P1) as PI negative and therefore as living cells (green cells). Cells marked by gate P2
are displayed in plot C by their PI signal against the EVOblue fluorescence of the cell lysate.
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3.2.6.4 H1373-GFP
The efficiency of the sorting procedure is dependent on significant and distinct fluores-
cence signals, which identify the target cell. A fluorescent marker clearly identifying
hybridoma clones would greatly facilitate cell sorting. This can be achieved e.g. by
stable transfection of Sp2/mIL-6 myeloma cells with GFP (transfection performed by
S. Vogel, Fraunhofer IME). To verify this hypothesis, these cells were used for a fusion
with B-cells derived from mouse 2 immunised with H1373 cell lysate. The resulting
hybridoma clones showed GFP-fluorescence 7 days after fusion in a microscopic con-
trol (3.20). Therefore the GFP fluorescence was used as sort criteria in an additional
single cell sorting.
A B
Figure 3.20: Microscopic image of hybridoma cells originating from a fusion of B-cells with GFP-
transfected Sp2/mIL-6 cells. A: transmitted light. B: UV-light.
The dot plots of the FACS are shown in figure 3.21. Plot A displays again the whole
population depending on the size (FSC-A) and granularity (SSC-A). Gate P1 defines
approximately the population of living cells (red cells). Plot B displays the whole cell
population dependent on the PI and GFP signal. The cells in quadrant Q4 are PI nega-
tive and therefore living cells, while they show a significant GFP signal which indicates
that these cells express GFP. These cells were sorted into 96well plates with sterile fil-
tered original culture medium supplemented with fresh medium and BM condimed
(3.2.4). Seven hundred and fourty four cells were sorted and 216 clones could be estab-
lished which is equivalent to 29%. Due to bacterial infection and stop of growth only
48 clones could be kept in culture.
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Figure 3.21: FACS analysis of H1373-GFP hybridoma with PI. In order to obtain living monoclonal
hybridoma cells, the hybridoma cells after fusion (2.2.4.4) were incubated with PI. These cells were
subjected into FACS analysis with subsequent single cell sorting of GFP positive and PI negative cells
(2.2.5.9). Plot A: size of the cells (FSC-A) is plotted against the granularity (SSC-A). Plot B: the GFP
signal, indicating the Sp2/mIL-6 origin, is plotted against the PI signal indicating the viability of the
cells. 1*107 cells from a H1373-GFP fusion were incubated with PI (2 µg/ml) immediately before FACS
analysis. Gate P1 (red) marks approximately the living cells depending on size and granularity. Cells in
quadrant Q4, which marks living (PI negative) cells with a significant GFP signal were sorted into 96well
plates.
3.2.6.5 PTL2
An additional sorting approach was carried out using the PTL2 hybridoma cells by
Florian Kampmeier (RWTH Aachen, BioVII, 2005). The PTL2 hybridoma cells were
incubated with fluorescently labelled pancreatitis lysate (2.2.2.4) to select for antigen
specific cells. To minimise the unspecific binding of other components of the tissue
lysate the lysate was pre-adsorbed by incubation with an established monoclonal hy-
bridoma cell line Bo9. This reduced the background staining. Figure 3.22 shows the
dot plots of the sorting experiment.
Plot A displays the whole cell population depending on size (FSC-A) and granu-
larity (SSC-A). The population of hybridoma based on size and granularity is defined
by gate P1. Unfused B-cells, apoptotic cells and cell debris were excluded because
they were smaller or show a higher granularity. Exclusively cells matching the char-
acteristics of the gate are displayed in plot B, depending on their fluorescence caused
by binding of the FITC-labelled anti-Ig antibody incubation with PI. Living cells with
significant FITC signal are marked by gate P2 and displayed in Plot C depending on
the EVOblue fluorescence. Cells with significant EVOblue signal (marked by gate P3)
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Figure 3.22: FACS analysis of PFL2-hybridoma with EVOblue labelled pancreatitis tissue lysate
and PI. In order to obtain living and cell lysate-specific monoclonal hybridoma cells, the hybridoma cells
after fusion (2.2.4.4) were incubated with EVOblue labelled cell lysate (2.2.2.4) and PI. These cells were
subjected into FACS analysis with subsequent single cell sorting of EVOblue positive and PI negative
cells (2.2.5.9). Plot A: size of the cells (FSC-A) is plotted against the granularity (SSC-A). Plot B: the
PI signal indicating the viability of the cells is plotted against the FITC signal indicating the presence
of surface Ig. Plot C: the EVOblue signal, indicating bound components of the tissue lysate, is plotted
against the PI signal. 1.2*107 cells from the PTL2 fusion were incubated with 50 µg SAMFITC . PI
(2 µg/ml) was added immediately before FACS analysis. Cells with different EVOblue signal (P3: white
gate, red gate, orange gate) were sorted into microwell plates. Gate P1: Pre-defined hybridoma cells
according size and granularity. Gate P2: Living (PI negative) hybridoma cells presenting surface Igs
(FITC positive).
were sorted into 96well plates with sterile filtered original culture medium supple-
mented with fresh medium and BM condimed (3.2.4) to achieve maximum single cell
growth. From the 1824 cells sorted, 340 hybridoma clones could be established. This
corresponds to a survival rate of approx. 19%.
3.2 Systemised Approach for High-Throughput Generation of Antibodies and
Identification of the Corresponding Antigens 77
3.2.7 Monoclonal Antibody Production
Three hundred and ninety four hybridoma clones were maintained in culture after
single cell sorting of H1373I, HFL1 and H1373-GFP hybridoma originating from im-
munisation of mice with lung cancer cell lines and every clone was tested for the pro-
duction of monoclonal antibodies (2.2.5.6).
The H1373I hybridoma (150 clones) were tested for the production of IgG and IgM
antibodies in a sandwich ELISA. Unfortunately the anti mouse IgG antibody signifi-
cantly cross reacted with the IgM isotype and made the isotype determination very
difficult. Hybridoma clones were specified as IgM if the supernatant showed a signal
in the anti IgG as well as in the anti IgM ELISA. In some cases hybridoma clones were
determined as IgG and later turned out to be IgM and the other way around. Therefore
the determination of the isotype by ELISA needs further refinement. However 25%
of the 150 tested clones showed significant signals (5-40x the signal of the negative
control) in the ELISA, and 22 clones were judged to be producing IgG.
The supernatants of the HFL1 hybridoma were used for an antigen ELISA. For this
purpose 500 ng/well of HFL1 cell lysate (2.2.2.1) was coated. The subsequent ELISA
was carried out as described in 2.2.5.6. One hundred and fifty clones were tested and
24 clones (16%) showed a significant signal (5-40x the signal of the negative control).
Due to growth arrest, bacterial infection or stop of antibody production of antibodies
during 6 weeks in culture 18 clones were discarded and only 6 stable cell lines (3x IgG,
3x IgM) were established.
An anti IgG ELISA was performed with the supernatants of the 94 H1373-GFP hy-
bridoma. Fifty one percent revealed significant signals (5-40x the signal of the negative
control). The statistics of the single cells culturing and ELISA are summarised in table
3.4.
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Table 3.4: Summary of single cell sorting and monoclonal antibody production
Hybridoma Sorted Surviving mAb N2-
storage
H1373I 480 150 37 37
22 IgG
15 IgM
HFL1 384 150 24 6
3 IgG
3 IgM
H1373-GFP 744 216 48 48
surviving after bacte-
rial infection: 94
Total 1608 516 91
For the 6 HFL1 clones an ELISA for the determination of the isotype was performed
(2.2.5.7). Due to financial limitations the isotyping was not done for all clones. The
results, which are shown in table 3.5 confirm the interpretations regarding the isotype
above.
One thousand eight hundred and twenty two cells were sorted and 340 clones (19%)
could be established by Florian Kampmeier (RWTH Aachen) from the PTL2 fusion.
Fourty of the 340 clones obtained were lost either because they stopped growing or
due to bacterial infection. Three hundred single hybridoma clones were maintained in
culture and approximately 230 were tested for the production of IgG or IgM antibodies
(2.2.5.6). About 44% of the tested hybridomas produced antibody. Fourty percent were
initially classified as IgG, 60% as IgM (F. Kampmeier, diploma thesis).
For further characterisation hybridoma clones were transferred into 25 cm2 bottles.
After reaching a cell density of approximately 106 cells/ml medium was changed to
CD(C) (2.1.2.2) for production of mAb and subsequent immunoprecipitation. This
medium is protein free and chemically defined for hybridoma growth and monoclonal
antibody production. Due to the protein free composition a subsequent purification
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Table 3.5: Determination of isotype
Clone Isotype
HFL1-1 IgG1
HFL1-4 IgG1
HFL1-14 IgM
HFL1-16 IgG4
HFL1-19 IgM
HFL1-22 IgM
of monoclonal antibodies was not required. Figure 3.23 shows a SDS-PAGE analysis
(2.2.5.3) of selected hybridoma supernatants. The hybridoma showed production rates
of estimated 25-100 µg/ml.
3.2.7.1 Antigen Identification
The immunoprecipitation with bead conjugated antibodies is a well known technique
and has been employed for several applications including the capturing of antigen
from complex mixtures with subsequent mass spec analysis. Nevertheless the captur-
ing and MS analysis is a multistep process and the setup had to be adapted and opti-
mised in many aspects to reach sufficient sensitivity and specificity.
Immunoprecipitation approaches were performed with hybridoma supernatants
of H1373I and H1373-GFP as described in 2.2.5.10. Binding of mAb to the GAM beads
was proven by FACS analysis (Figure 3.24). The coated beads were incubated with
SAMFITC (2.2) and the shift in the FITC channel compared to the uncoated beads cor-
relates with the amount of mouse antibody bound. The histograms of the FACS are
displayed in figure 3.24. In comparison to the negative control (incubated only with
medium; grey filled curve) the samples with antibodies showed a significant shift in
fluorescence. Comparisons of the fluorescence shift with a control antibody (CA19.9)
(data not shown) showed that the fluorescence intensity raises in a proportional way
with the amount of antibody coated until a maximum (approx. 10 µg) is reached. In
all experiments a minimum of 50% of this maximum was reached.
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Figure 3.23: SDS-PAGE of serumfree hybridoma culture supernatants under reducing conditions.
In order to check the production and integrity of mAb NP78 SDS-PAGE analysis was performed (2.2.5.3).
Hybridoma supernatants (15 µl) were loaded onto a NuPAGETM gel in the MES buffer system under
reducing conditions. Proteins were visualised by staining with 0.25% (w/v) Coomassie brilliant blue
(2.1.2.1). M: Prestained protein marker SeeBlue (Invitrogen); PC = 2 µg of mAb CA19.9; Lane 2-5
= Hybridoma supernatant of mAb H1373-GFP clone number 5, 29, 20, 48; Lane 7-8 = Hybridoma
supernatant of mAb H1373I clone number 35, 68.
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Figure 3.24: FACS analysis of GAM beads coated with antibody. The successful coating of mAb to
GAM beads was proven by FACS analysis (2.2.5.8). Plot A: size of the beads (FSC-H) is plotted against
the granularity (SSC-H). Plot B: the FITC signal of the whole bead population is plotted against bead
counts. 3 µl of beads after incubation with medium and supernatant (2.2.5.10) were incubated with 10
µg SAMFITC . 10000 beads were measured each. Grey filled curve: beads coated with CD(C) (negative
control); green curve: H1373-GFP-42; blue curve: H1373-GFP-44; red curve: H1373-GFP-48; bright
blue curve: H1373I-3; purple curve: H1373I-35.
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Successful coated beads were furthermore incubated with freshly prepared cell
lysate (2.2.5.10). Following the immunoprecipitation the elution fractions were sepa-
rated and analysed by SDS-PAGE (2.2.5.3) and silver staining (2.2.5.4) in comparison
to a negative control (NC), where no mouse antibody was coated to the beads. Fig-
ure 3.25 shows one stained SDS-PAGE as example. Bands which were visible in the
sample lanes but not in the NC are marked and were subsequently digested and anal-
ysed by MS as described in 2.2.6.2 - 2.2.6.3. In this analysis the protein bands could
not be identified, because no protein could be detected (M. Kuepper, RWTH Aachen,
personal communication). Indeed, the loss of protein during the in gel digestion and
desalting is very high. Only band 10 was identified, but with a low score of 39 [50], as
murine kappa light chain. The score indicates the probability that the match found in
the database is really the protein isolated. The individual ion score is –10*Log(p). The
value for p = 0.05 indicating identity or extensive homology is shown in parentheses.
Figure 3.25: Immunoprecipitation and silver staining of the eluted proteins. Immunoprecipitation
was performed as described in 2.2.5.10. Neutralised elution fractions were loaded onto a NuPAGETM
gel in the MES buffer system. Lysate: 6.5 µl of cell lysate (2.2.2.1); M: Prestained protein marker
SeeBlue (Invitrogen); Lane 3-7: GAM beads + hybridoma supernatant + H1373 cell lysate; NC: Negative
control, GAM beads incubated with H1373 cell lysate.
Similiar experiments were performed with PTL2 monoclonal hybridoma clones (F.
Kampmeier, RWTH Aachen, BioVII, 2005). Successful coating of antibody to Prote-
inG beads was also proven by FACS (data not shown), where clear shifts could be
shown. The coated beads were used for immunoprecipitation (2.2.5.10) as described.
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After SDS-PAGE (2.2.5.3) and silver staining (2.2.5.4) of the eluted proteins, bands not
present in the NC, but in the sample lanes were cut out and analysed by MS analysis
(2.2.6.3). One gel is shown in figure 3.26 (complete results see diploma thesis F. Kamp-
meier, RWTH Aachen, BioVII, 2005). The marked bands around 15 kDa of the mAb
(PTL2 hybridoma) 130, 112, 152 could be identified as beta-globin. The band around
50 kDa from precipitation with the mAb 17 was identified as human pancreatic alpha
amylase 2a, an enzyme of the starch metabolism produced in the pancreas. As example
the results of the MS analysis are shown in table 3.6 and table 3.7 (further information
are in shown in the diploma thesis, F. Kampmeier, RWTH Aachen, BioVII, 2005).
Figure 3.26: Immunoprecipitation and silver staining of the eluted proteins. Immunoprecipitation
was performed as described in 2.2.5.10. Neutralised elution fractions were loaded onto a NuPAGETM
gel in the MES buffer system. M: protein marker SeeBluePlus2 (Invitrogen); Lane 1-6: GAM beads
+ hybridoma supernatant + pancreatic tissue lysate; NC: Negative control, GAM beads incubated with
pancreatitis cell lysate; PC: Positive control, mAb anti CA19-9, 500ng.
Pancreatitis is an inflammation and therefore suppliedwith blood in a high fashion,
probably leading to high concentration of beta globin chains. Amylase is reported to
have an 3-fold increased serum concentration due to pancreatic disesases (STEEN et al.,
1990; IGNJATOVIC et al., 2000). Therefore, both proteins are present at high amounts in
the cells and therefore should have high concentrations in the lysates. But due to the
strong background in the negative control and the samples it was difficult to identify
variable protein bands at lower concentrations. Furthermore due to the high sensivity
of the silver staining a very strong signal is required for a subsequent identification
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Table 3.6: MS Identification of beta globin chain variant
Match to: beta globin chain variant
(Homo sapiens)
Score: 391 [52]
NCBI database reference: gi|26892090
Sequence Coverage: 94%
Complete AA sequence of beta globin. Matched peptides in red:
M V H L T P E E K S A V T A LW G K V N V D E V G G E A L G R L L V V Y PW T Q R F
F E S F G D L S T P D A V M G N P K V K A H G K K V L G A F S D G L A H L D N L K G
T F A T L S E L H C D K L H V D P E N F R L L G N V L V C V L A H H F G K E F T P P V
Q A A Y Q K V V A G V A N A L A H K Y H
Table 3.7: MS Identification of amylase
Match to: amylase alpha 2A, pancreatic
precursor (Homo sapiens)
Score: 135 [52]
NCBI database reference: gi|4502085
Sequence Coverage: 12%
Complete AA sequence of amylase. Matched peptides in red:
M K F F L L L F T I G F C W A Q Y S P N T Q Q G R T S I V H L F E W RW V D I A L E C
E R Y L A P K G F G G V Q V S P P N E N V A I Y N P F R P WW E R Y Q P V S Y K L C T
R S G N E D E F R N M V T R C N N V G V R I Y V D A V I N HM C G N A V S A G T S S
T C G S Y F N P G S R D F P A V P Y S GWD F N D G K C K T G S G D I E N Y N D A T Q
V R D C R L T G L L D L A L E K D Y V R S K I A E YMNH L I D I G V A G F R L D A S K
H MW P G D I K A I L D K L H N L N S N W F P A G S K P F I Y Q E V I D L G G E P I K
S S D Y F G N G R V T E F K Y G A K L G T V I R K WN G E KM S Y L K NWG E GWG
F V P S D R A L V F V D NH DN Q R G H G A G G A S I L T F W D A R L Y K MA V G F
M L A H P Y G F T R V M S S Y R W P R Q F Q N G N D V N DW V G P P N N N G V I K
E V T I N P D T T C G N DW V C EH RW R Q I R N M V I F R N V V D G Q P F T NW Y
D N G S N Q V A F G R G N R G F I V F N N D DW S F S L T L Q T G L P A G T Y C D V I
S G D K I N G N C T G I K I Y V S D D G K A H F S I S N S A E D P F I A I H A E S K L
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using MS. This is due to the very high loss of protein during the sample preparation
for the MS analysis resulting in too small amounts of protein for successful analysis
(M.Kuepper, RWTH Aachen, personal communication). It should be possible to re-
duce the loss of protein by direct digestion and analysis of the eluted proteins without
separating SDS gel. However, the MS has to be improved, because the identification of
a fmol of protein should be possible in theory.
As proof of principle of this hypothesis 40 µg of an anti CD64 IgG1 antibody (H22)
(2.2) was coated onto protein A beads. Coated beadswere incubated with 200 µl H1373
cell lysate (2.2.2.1) spiked with 8 µg of purified human CD64, kindly provided by
A. Paetz (RWTH-Aachen). Capture and MS analysis were performed as described
in 2.2.5.10, 2.2.6.1 and 2.2.6.3). CD64 was captured and identified with a very high
probability, even though the total amount of peptide found in the MS was very low in
comparison to the 8 µg of CD64 added to the lysate. The negative control contained
only the beads incubated with cell lysate, which lead to no significant hit (data not
shown). The results of the analysis are shown in table 3.8.
Table 3.8: MS Identification of hCD64
Match to: human high affinity Fc receptor
(FcRI) (Homo sapiens)
Score: 142 (52)
NCBI database reference: gi|31332
Sequence Coverage: 14%
Complete AA sequence of human CD64. Matched peptides in red:
V T L Q P P W V S V F Q E E T V T L H C E V L H L P G S S S T Q W F L N G T A T Q T S
T P S Y R I T S A S V N D S G E Y R C Q R G L S G R S D P I Q L E I H R GW L L L Q V S S
R V F T E G E P L A L R C H AW K D K L V Y N V L Y Y R N G K A F K F F HWN S N L
T I L K T N I S H N G T Y H C S GM G K H R Y T S A G I S V T V K E L F P A P V L N A S
V T S P L L E G N L V T L S C E T K L L L Q R P G L Q L Y F S F Y M G S K T L R G R N T
S S E Y Q I L T A R R E D S G L YW C E A A T E D G N V L K R S P E L E L Q V L G L Q L
P T P VW F H V E Q K L I S E E D L N S A V D
A second well known antibody was used to confirm the results of immunopre-
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cipitation and subsequent antigen identification. The monoclonal antibody Bo9 binds
specifically the PV timothy grass pollen allergen. The antibody was coated to protein
G beads and incubated with pancreatic carcinoma/pancreatitis lysate (2.2.2.2), spiked
with a PV-ETA fusion protein consisting of the first half of the PV timothy grass pollen
allergen and a truncated mutant of the Pseudomonas exotoxin A. One significant hit
was found in this case identifying the PV part of the fusion protein. The complete
result is shown below (Table 3.9).
Table 3.9: MS Identification of allergen Phl p Vb
Match to: allergen Phl p Vb (common timothy)
Score: 62 (50)
NCBI database reference: gi|481397
Sequence Coverage: 3%
Complete AA sequence of allergen Phl p Vb. Matched peptides in red:
M A V P R R G P R G G P G R S Y T A D A G Y A P A T P A A A G A AA G K A T T E E Q
K L I E D I N V G F K A A V A A R Q R P A A D K F K T F E A A S P R H P R P L R Q G A
G L V P K L D A A Y S V A Y K A A V G A T P E A K F D S F V A S L T E A L R V I A G A
L E V H A V K P V T E E P G M A K I P A G E L Q I I D K I D A A F K V A A T A A A T A
P A D D K F T V F E A A F N K A I K E S T G G A Y D T Y K C I P S L E A A V K Q A Y A
A T V A A A A E V K Y A V F E A A L T K A I T A M S E V Q K V S Q P A T G A A T V A
A G A A T T A A G A A S G A A T V A A G G Y K V
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Following this protocol successful immunoprecipitation procedures with identifi-
cation of the antigen were also performed with two hybridoma clones (HFL1-1 and
HFL1-22). Protein A magneto beads were incubated with supernatant of the HFL1-1
and HFL1-22 hybridoma, respectively. The successful coating of antibody to the beads
was proven by FACS (2.2.5.8). For this purpose coated Protein A beads were incubated
with SAMPE. The histogram of the FACS analysis is shown in figure 3.27 and figure
3.28. Successful binding of the antibodies to the beads is indicated by the shift in the
PE fluorescence in comparison to the negative control (green curve).
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Figure 3.27: FACS analysis of Protein A beads coated with HFL1-1. The successful coating of
mAb HFL1-1 to GAM beads was proven by FACS analysis (2.2.5.8). Plot A: size of the beads (FSC-
H) is plotted against the granularity (SSC-H). Plot B: the PE signal of the whole bead population is
plotted against bead counts. 3 µl of beads after incubation with medium and supernatant (2.2.5.10)
were incubated with 10 µg SAMPE . 10000 beads were measured each. Grey filled curve: beads green
curve: beads coated with CD(C) (negative control); red curve: beads coated with HFL1-1.
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Figure 3.28: FACS analysis of Protein A beads coated with HFL1-22. The successful coating of
mAb HFL1-22 to GAM beads was proven by FACS analysis (2.2.5.8). Plot A: size of the beads (FSC-
H) is plotted against the granularity (SSC-H). Plot B: the PE signal of the whole bead population is
plotted against bead counts. 3 µl of beads after incubation with medium and supernatant (2.2.5.10)
were incubated with 10 µg SAMPE . 10000 beads were measured each. Grey filled curve: beads green
curve: beads coated with CD(C) (negative control); red curve: beads coated with HFL1-22.
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For immunoprecipitation freshly prepared HFL1 cell lysate (2.2.2.1) was added.
Proteins were eluted with 0.1 M Citrate buffer (pH3.3). The MS analysis was per-
formed by Toplab (Munich). Two proteins were identified binding to HFL1-1, while
in case of HFL1-22 one protein could be identified. The results are shown below. The
peptides found were not transferred from Toplab.
Table 3.10: MS Identification of HFL1-1 antigen
Match to: dedicator of cytokinesis protein 5
(Homo sapiens)
similar to eucaryotic translation ini-
tiation factor 4E nuclear import fac-
tor 1
NCBI database reference: gi|32469780
gi|22766926
Table 3.11: MS Identification of HFL1-22 antigen
Match to: similar to CG5882-PA (Homo sapi-
ens)
NCBI database reference: gi|27498927
Sequence Coverage: 18%
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3.2.7.2 Molecular Imaging of the HFL1-22 Antigen
One region of the human protein binding to the mAb HFL1-22, which is similar to
CG5882-PA codes for the myosin tail which indicates the localisation of the whole pro-
tein to the membrane. Due to this the binding of the mAbHFL1-22 could be studied by
molecular imaging. Imaging was performed as described in 2.2.5.11. Successful stain-
ing of the nucleus and the targeted protein is shown on both cell lines used (HFL1,
LS174T). The pictures of the microscopic analysis are shown in figure 3.29.
A1 A2 A3
B1 B2 B3
Figure 3.29: Molecular imaging of the HFL1-22 antigen. Cell staining of cells (LS174, HFL1) was per-
formed as described in 2.2.5.11. Cells were incubated with 200 µl of HFL1-22 hybridoma supernatant.
As detection antibody 2 µg/well GAMAlexa488 (green fluorescence) was used. The nucleus was stained
with DRAQ5 (red fluorescence). Measurement was carried out using the OPERA system (Evotec).
Chapter 4
Discussion
4.1 Generation of a NP-specific Antibody
In the first chapter of this thesis the generation of NP-specific antibodies is described.
NP is considered to be an endocrine disrupting substance. Significant amounts of NP
are present in water and sludge of rivers. Synthetic hormones like NP show high
persistence in the environment and due to several endocrine effects on aquatic or-
ganism strategies for its elimination have to be developed. The AGEESA focusses on
several approaches, including membrane technology and microbial degradation. This
project could contribute to the development of biofilters. These filters could consist
of plant cells or algae carrying receptor molecules or antibodies binding to estrogenic
substances on their surface. To reach this long term goal, an antibody binding to NP
should be developed within this project. NP had to be coupled to the immunogenic
carrier cBSA to provoke an immune response to the hapten NP. The immunisation of
mice was carried out with different strategies followed by the immortalisation of the
splenic mouse cells by fusion with mouse myeloma cells. Binding of the antibodies to
NP was proven by ELISA and NP-capturing of one antibody with subsequent GCMS
analysis.
4.1.1 Coupling of NP to cBSA
The hapten NP is a phenolic compound with a molecular mass of 220 g/mol. Haptens
are unable to induce an immune response by themselves due to their low molecular
weight (< 300 g/mol). Therefore antibodies can only be raised against larger derivates
of NP associated to an immunogenic protein (CHAPPEY et al., 1994). Because most
proteins contain both exposed lysines and carboxyl groups, EDC mediated immuno-
gen formation is a simple method for the majority of protein-carrier conjugations.
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The Imject R© SuperCarrier R© EDC System (Pierce) was used to couple NP to BSA. The
SuperCarrier R© Immune Modulator is BSA that has been modified by substituting an-
ionic carboxyl groups with cationic aminoethylamide groups. This cationised BSA
(cBSA) is reported to induce a stronger immune response than native BSA (MUCKER-
HEIDE et al., 1987). In theory, cBSA is believed to have a greater affinity to the negatively
charged cell surface of antigen presenting cells and therefore leads to a more efficient
uptake, processing and presentation of the antigen, resulting in an enhanced immune
response (APPLE et al., 1988). The EDC (1-ethyl-3-[3-dimethylaminopropyl]carbodi-
imide hydrochloride) reacts with carboxyl and amine groups to form stable amide
bonds. Because carboxyl groups on cBSA have been modified, conjugations are site-
specific to cBSA amino groups. Therefore cBSA was chosen for the conjugation of the
hapten (3.1.1). Alternatives for cBSA could have been the keyhole limpet hemocyanin
(KLH), which is used as a standard carrier (MORAN et al., 2002). But probably due to
the extreme high molecular weight of KLH and the lipophilic nature of NP strong pre-
cipitations might have occured at the initial steps of the coupling reaction. Furthermore
the lipopeptide Pam3Cys-TH is reported to be the most immunogenic carrier molecule
and leads to higher immune responses than cBSA (MORAN et al., 2002). But this may be
related to the long linker region of 5 C-atoms introduced into the immunogen by this
peptide, which leads to an anti-hapten immune response, which is discussed below.
NP itself possesses a long alkane chain of 9 C-atoms, which could serve as an extanded
linker residue.
Here, 0.32 mg NP of the initial amount of 0.5 mg were coupled to cBSA. In this
coupling reaction the initial hapten-to-protein molar ratio was 75:1, as suggested by
the kit instruction, resulting in a substitution of 63%. These values are in the same
range compared to other conjugation reactions (TUOMOLA et al., 2000). TUOMOLA et al.
found 32% of substitution after initial molar ratios of 25:1 in case of BSA as carrier and
approximately 50% after initial molar ratios of 50:1 in case of BGT (bovine thyroglobin)
as carrier.
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4.1.2 Immunisation of Mice with NP-cBSA
It is very difficult to raise an immune response against non-immunogenic haptens.
Beside the choice of an immunogenic carrier the immunisation strategy can play an
important role in the elicitation of an immune response. Immunisation with a hap-
ten conjugated to a more immunogenic carrier molecule can lead to the generation of
antibodies against epitopes of the carrier molecule. One way to avoid this problem
is to tolerise mice against the dominant protein by injections of high amounts of this
protein prior to immunisation with the hapten-carrier mixture. LEBRON et al. (1999)
successfully used this so called High Zone Tolerance to generate antibodies specific to
heterodimeric proteins.
In the presence of high amounts of such a protein (tolerogen) the T-cells with the
corresponding antigen specificity do not receive the secondary signals, from antigen
presenting cells, required for T-cell activation. The immune system enters a state of
anergy and tolerogen specific B-cells fail to obtain T-cell support, followed by elimina-
tion or inactivation. As a result the tolerance inhibits the tolerogen-specific immune
response (FUCHS and MATZINGER, 1992). During the immunisation with the anti-
gen of interest primarily epitopes of this antigen, that means epitopes which were not
present on the tolerogen, are targeted by the immune system and a humoral response
is provoked.
High Zone Tolerance is induced if animals are immunised with high doeses of pro-
tein in the absence of adjuvants (ZIJLSTRA et al., 2003). LEBRON et al., (1999) induced
tolerance against the high immunogenic antigen by two subcutaneous injections of 250
µgwithout any adjuvants, followed by 3 injections of 10 µg of the heterodimers includ-
ing adjuvants into 5-week-old female BALB/c mice. In the absence of the tolerising
step only 1–3% of the resulting hybridomas reacted with the heterodimer and not the
tolerogen. In contrast, following tolerisation, up to 93% of the hybridoma clones ex-
hibited this specific reactivity.
Based on these results three different immunisation strategies were used for the
immunisation of the three mice with NP (2.7). Unfortunately the mouse which was
immunised according to the scheme of LEBRON et al. died before the final endpoint
of the serum titre could be determined. The titre of the mouse which received the
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two initial boosts of 250 µg cBSA was significantly higher than the titre of the mouse
did not receive booster injections. Due to the preincubation of the serums with BSA
no signal could be detected on the reference plate coated with cBSA alone. Remark-
ably are the relative low signal in the ELISA and the low dilution factor of the serum
(1:1000), which revealed a signal two-fold higher than the negative control. These re-
sults may be due to the fact that the NP amount per well was very low. The wells
were coated with 500 ng NP-cBSA conjugate, but if for example 10 molecules of NP
are coupled to one molecule of cBSA only approx. 20 ng of NP were coated per well,
to which specific antibody can bind. So the amount of NP per well is only a fraction
of the amount of cBSA. Additionally the small NP-molecule could be masked by BSA
protein chains. Nevertheless the signal was judged as sufficient for the generation of
hybridoma clones.
However, these results confirm the successful tolerisation of the mouse, because
a significant higher immune response could be shown after the tolerisation protocol.
Further improvement of the hapten specific immune response could be reached by
novel immunisation protocel provocing the drug induced tolerance. The tolerogen is
injected together with nitrogen mustard cyclophosphamide (Cy), which is able to to-
lerise animals to Non-Self antigens (SCHWARTZ and DAMESHEK, 1953). The ability
is based upon the ability of Cy to preferentially eliminate antigen stimulated B- and
T-cells (BERENBAUM et al., 1967). MATTHEW and PATTERSON (1983) were the first to
exploit the ability of Cy to alter the immune response in order to augment the produc-
tion of specific mAbs. Their objective was to generate antibodies which block neurite
outgrowth induced by an heparan sulfate proteoglycan. Standard immunisations only
led to antibodies incapable to block the function. This is not the only example for the
successful drug induced tolerisation and therefore Cy-mediated augmentation has be-
come the method of choice for the generation of antibodies to epitopes with no or low
immunogenicity.
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4.1.3 Immortalisation of Spleen Cells and Fluorescence Activated
Cell Sorting
The decision to sacrifice a mouse was made on ELISA data (3.1.2). Spleen cells were
isolated and fused with Sp2/mIL-6 cells as described (2.2.4.4). Instead of the labour
intensive limiting dilution steps it was decided to substitute the hybridoma cloning
using FACS. This cloning strategy has several advantages in comparison to the limit-
ing dilution procedure. It is a quick and easy method. Single clones are obtained in
only one sorting step which eliminates the risk of overgrowth of valuable clones by
others. Additionally viable cells from cultures containing only a few viable cells can be
cloned with high efficiency. The FACS is an efficient tool for antigen specific cloning of
antibody producing hybridoma cells (PARKS et al., 1979).
Within the scope of this thesis two different single cell sorting approaches were
performed to obtain monoclonal antibodies against NP. In a first approach living cells
were isolated out of the whole fusion culture 7 days after fusion according to their
light scattering and the PI signal. PI enters the membrane of dead cells and there-
fore marks them fluorescently. Cells were sorted into a mixture of conditioned culture
medium and fresh HAT medium. Sp2/mIL-6 cells, which were used for spleen cell
immortalisation, produce constitutively murine IL-6 (mIL-6). This B-cell growth fac-
tor promotes the growth and stability of freshly fused hybridomas and is often used
to supplement the cloning media as an alternative to a macrophage feeder cell layer,
which is circuitous (PETERS and BAUMGARTEN, 1990; HARRIS et al., 1992). The condi-
tioned medium should contain mIL-6 in sufficient amounts to enhance the survival of
the sorted cells. Nevertheless the surviving rate in this approach was only 10% which
needed to be improved.
Therefore in the next sorting approach the cells were sorted in 100% conditioned
medium to increase the concentration of the growth factors. This led to a survival rate
of 30%, which was satisfying but can surely be further increased through more sys-
tematic studies, with sorting of one hybridoma batch into different media containing
different percentages of conditioned and fresh medium and hybridoma supplement.
In other sorting experiments different media compositions were used and amongst
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others the mixture of conditioned and fresh medium was the best choice in some sort-
ing approaches. Sensitive factors (waste of the conditioned medium and abscence of
important growth factors for example) may play an important role and complicate op-
timisation and reproduction.
In addition fluorescently labelled NP was used as an additional sorting criteria to
achieve an antigen specific cloning. It is difficult to evaluate the success of this ap-
proach. Nevertheless from this approach 8 clones which showed binding in the ELISA
to NP were isolated (3.1.4.1) which corresponds to 15.4% of the surviving clones, while
3 clones producing antibodies against NPwere obtained from the first approach, which
is equivalent to 8.6% of the growing clones. The cloning of the hybridoma was very
fast and high numbers of clones can be obtained in a short time. However, the relative
low number of analysed clones and the significant difference in survival rates makes it
difficult to make a definite statement in terms of specificity and efficiency of the sort-
ing. Nevertheless automated FACS provides the opportunity of fast and easy supply
of monoclonal hybridoma and is even reported to rescue 1 viable cell out of 3200 dead
cells (PARKS et al., 1979). The growth rate of 30% appears to be low, but due to the
sensitive sorting settings, it was guaranteed that a maximum of 1 cell was sorted per
well, which includes possible empty wells.
4.1.4 Characterisation of mAb
Two assays were carried out to analyse the binding of the isolated antibodies to NP. In
the literature only indirect ELISA are described for the detection of NP (ZERAVIK et al.,
2004). Firstly an ELISA coated with NP-cBSA and a reference plate with cBSAwas per-
formed to screen the single clones after fluorescent activated sorting. The supernatant
of all growing clones (87) was tested and in case of 11 clones a significant signal was
measured on NP-cBSA, but not on cBSA alone. This is a clear hint for the production
of mAbs against NP.
However it is not clear if the antibodies were specific for NP alone or if the peptide
linkage between NP and cBSA also plays a role in detection. Experiments to perform
an ELISA with coated NP alone failed, probably due to the small size of NP, which is
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masked on the surface of the plate by the coating reagents. TUOMOLA et al. (2000) have
shown that haptens with a short bridging group (1-2 C-atoms) between the hapten and
the carrier fail to initiate anti-hapten antibodies while longer bridging groups lead to
antibody generation against the hapten. A possible explanation for this could be that
the hapten conjugated by a short linker may be masked within the protein structure,
while with a long linker the hapten can be projected above the carrier protein surface
(PAXTON et al., 1976). In the work presented here NP with a linear alkan chain (9 C-
atoms) coupled via carboxy group at the end of the alkan chain to cBSA was used. This
may lead to the assumption that an immune response against the phenolring could be
elicited, because of the long bridge consisting of the alkan chain. In addition this long
spacer chain could lead to a higher specificity toward the side substituent (phenolring)
of NP (ZERAVIK, 2004).
In order to proof the binding of the antibodies to NP without carrier and the link-
age to the carrier an immunoprecipitation with subsequent GCMS analysis was per-
formed (3.1.4.3). This assay was performed with the only antibody which showed
stable growth and antibody production behaviour over months (NP78). Based on the
capacity of the beads the amount of coated antibody was between 5 and 10 µg, which
based on molarities enables the binding of 15-30 ng NP. NP is very lipophilic and sticks
to almost every material. For this reason 60 ng of NP were applied to the assay, so that
after saturation of the surfaces with NP, enough NP stays in solution for the measure-
ment. The GCMS analysis revealed that the supernatant of the beads coated with the
anti-NP antibody contained only half the amount as in the control. These results indi-
cate specific binding of the antibody NP78 to NP.
4.1.5 Conclusion
The first aim was the generation of an antibody against the hapten Nonylphenol in
the scope of the Graduate College for the Elimination of Endocrine Disrupting Sub-
stances from waste water (AGEESA). The immunisation strategy using the High Zone
Tolerisation led to an increased immune response to the hapten. The cloning proce-
dure could be simplified and accelerated by automated single cell sorting. To reach a
statistical relevant conclusion about the antigen specific sorting more clones have to be
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analysed inmore detail in the future. Nevertheless the cloning by single cell sorting led
to monoclonal antibodies in one fast step. A binding assay was established using the
immunoprecipitation of NP by an antibody coupled to beads. Using this binding assay
with the monoclonal antibody NP78 proved the successful binding of the antibody to
unbranched NP.
4.1.6 Outlook
The long term goal of the project AGEESA is to identify methods for the elimination
of endocrine disrupting substances from waste water. For this purpose an antibody
against NP was generated in this work. In further work it has now to be investigated if
this antibody binds to all kinds of phenols or nonylphenols or if the binding is specific
for non branched NP. This can be carried out using the immunoprecipitation method
and subsequent GCMS analysis described here. In parallel, the genetic information of
the antibody has to be isolated and analysed in comparison to the three left and yet un-
characterised clones. The information could be used for the expression of the antibody
on the surface of plant cells or algae. These cells could be used for the construction
of a biofilter to eliminate NP from waste water. The binding of NP to the antibody
located on the surface of the plant cell have to be investigated under the typical condi-
tions present in sewage treatment plants. In the end, biofilter can provide a powerful
method for the elimination of various substances from drinking water.
4.2 Systemised Approach for High-Throughput Gener-
ation of Antibodies and Identification of the Corre-
sponding Antigens
There is a need for the development of new diagnostic tools in terms to individualise
diagnosis and therapy and for the development of more efficient diagnosis tools for
the early diagnosis of diseases. Advances were reached using DNA micorarray for
the analysis of gene expression in malignant tissues. However, analysis on the DNA
level does not mirror the state on the protein level regarding total amounts and post-
4.2 Systemised Approach for High-Throughput Generation of Antibodies and
Identification of the Corresponding Antigens 97
translational modifications. Recent studies showed that antibody microarrays provide
good features for the monitoring of the composition of sera or tissue samples on a
protein level.
The long term goal of the project described here is to set up antibody microarrays
as diagnosis tools. The diagnosis should be realised by the detection of disease specific
protein pattern using antibody microarrays. The basis to reach this goal is a whole set
of antibodies specific for human proteins from which candidates can be choosen for a
disease specific microarray set up. Antibodies are natural molecules, which are highly
specific for their target. Furthermore a variety of antibodies can be developed for the
same protein targeting different epitopes.
Here two approaches were investigated for their utility for the randomised pro-
teome wide high throughput generation of antibodies and the identification of the cor-
responding antigens using the proteome of the lung and pancreas as model.
4.2.1 Phage Display Approach
Phage display is a promising technology in the field of high throughput generation
of antibodies against a variety of proteins. It enables the selection of antigen binding
fragments out of huge antibody repertoires. 2-D gel electrophoresis is still the most
commonly and most successfully used proteomics method for the separation and vi-
sualization of proteins and it has been applied for the identification of differentially
expressed proteins in various types of human cancers. Combining these two tech-
niques could provide a suitable platform for the establishment of a procedure for the
selection of antibodies on a variety of antigens in parallel (L IU et al., 2002). Therefore
proteins of lung cancer cell lysates were separated by 2D-PAGE, blotted onto Nitro-
cellulose membrane and incubated with a scFv phage display library. In a first phage
display the number of spots on the membrane was not satisfying. This number could
get increased in a following phage display using a library after successful enrichment
on lung cancer cells. Nevertheless a variety of problems occurred. Because blocking
agents are bound to the membrane in vast excess over antigen, they become targets
for selection even when free blocking agents are present in the binding solution as
competitor (LIU et al., 2002). The background caused by unspecific binding could be
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reduced but not eliminated by blocking with fish gelatine in contrast to blocking solu-
tions containing BSA or milk powder. Furthermore it was impossible to isolate the spe-
cific binding phages as monoclonal or oligoclonal phages from the membrane. Labour
intensive screening of reinfected and picked single phageswould have to be performed
to identify the specific binder. Due to the lack of a spot picker and accordant software
for the identification of the corresponding spots on the 2D-PAGE the identification of
the antigen failed. This approach was not feasable for the high throughput generation
of antibodies and identification of the corrsponding antigens and therefore an alter-
native was established based on the generation of hybridoma for the production of
monoclonal antibodies.
4.2.2 Hybridoma Approach
The hybridoma technique is used traditionally for the production of monoclonal anti-
bodies (MCCAFFERTY et al., 1990). It is labour intensive, but attractive due to the fast
availability of monoclonal full size antibodies, easy suitable for coupling of the anti-
bodies to e.g. affinity matrices on beads and chips and its feasibility for high through-
put approaches once specific equipment is established.
4.2.2.1 Immunisation of Mice
Standard immunisation protocols describe injections of 10-50 µg of protein (RATHJEN
et al., 1986), but these data relate to immunisations with defined and purified pro-
tein. However, they cannot be projected to complex mixtures of proteins from tissue
or cell lysates. Within this project it was required to raise an immune response against
as many different proteins as possible. Whole cells are known as good immunogens
presenting numerous targets on the cell surface, which make them suitable for immu-
nisations (SHAKIL et al., 2001). For the generation of antibodies against intracellular
targets and in order to generate antibodies against every protein of the cell immuni-
sation with cell lysates is required. Lysates of tissues are also reported to provoke a
specific immune response (LAMPE et al., 2004). Nevertheless a successful strategy for
immunisation is hard to predict. Lysates include a variety of different proteins in dif-
ferent concentrations. The immunogenicity of each protein is crucial for the outcome
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of the immunisation. The overall protein amount has to be balanced. Too high amount
of certain proteins could induce tolerance, while low amounts could fail to induce an
immune response (ZIJLSTRA et al., 2003; PETERS and BAUMGARTEN, 1990).
Two mice were immunised with whole cells and cell lysates respectively. The ex-
act composition of the cell lysate could not be determined. 2D-PAGE revealed that
the lysates include at least 300 (HFL1, data not shown) and 500-600 (H1373, 3.2.1.1)
different proteins respectively visible by eye. 50-100 µg/boost were injected s.c. per
mouse which corresponds to an average amount of 100-200 ng/protein. Despite this
small amount of protein an immune response could be evoked. Due to the variety
of immunogens the development of IgG as well as IgM antibodies was expected and
therefore the determination of both titres was carried out in combination for the H1373
and HFL1 immunised mice. All antibody serum titres rise in an almost exponential
manner. The immunisation as well as the titre determination of the pancreatitis lysate
immunised mouse was done by F. Kampmeier (RWTH Aachen). As expected the first
immune response led to an increase of the IgM titre. Due to repetitive boosts the B-
cells performed a class switch and started the production of high affinity antibodies of
mainly but not exclusively the IgG isotype, and a decrease of the IgM titre.
The fact that the serum antibody titre was relatively low may be due to the compo-
sition of the lysate. The signal strength in the ELISA depends on the amount of coated
protein, but the coating efficiency is depending on the characteristics of each antigen.
High abundant proteins may not necessarily have to be the most immunogenic pro-
teins. Therefore generated antibodies in the serum may only bind to a smaller part
of the coated proteins resulting in a low signal. The fact that about 40-60% of the
hybridoma clones that were generated from the spleens are of the IgM type could indi-
cate that many of the fused B-cells could not be stimulated strong enough to perform a
class switch and no secondary immune response was induced. Another reason could
be the variety of different antigen classes (protein, carbohydrates, lipids) leading to
antibodies of different isotypes (JANEWAY et al., 2002). However, using slightly higher
antigen dosages in the low milligram range might have led to a stronger immune res-
ponse (LAMPE et al., 2004).
The complexity of the antigen mixture turned out to be problematic in additional
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steps during this project. An effective and reproducible pre-fractionating step would
have solved these problems by providing a less complex and more defined antigen
source and enable the enrichment of low abundant proteins (STASYK and HUBER,
2004). Multidimensional liquid chromatography provides a promising tool for high
throughput protein analysis (SHEN et al., 2001). It overcomes most of the drawbacks of
the 2D-PAGE and is highly suitable for complete automation and reproducable frac-
tionating (WANG and HANASH, 2003). By combining different separation strategies as
ion exchange, isoelectric focusing and multiple HPLC columns there are e.g. no limi-
tations in terms of protein size. Low abundant proteins can be enriched and therefore
be detected with a higher sensitivity. Very basic proteins or proteins with several hy-
drophobic trans-membrane domains can be analysed. In addition these systems can
be coupled directly to MS analysis, proteins are on-column digested and measured
on-line.
4.2.2.2 Immortalisation of Murine B-cells and Antigen Specific Single Cell Sort-
ing
The decision to sacrifice a mouse was made based on the serum antibody titre values.
Spleen cells were isolated and fused with Sp2/mIL-6 cells. Employing a cell sieve in-
creased the number of spleenocytes isolated. The cell sieve enabled a fast, gentle, clean
and effective isolation of spleenocytes for the fusion in contrast to other methods, e.g.
perfusion of the spleen. Exact fusion efficiencies could not be determined, because mi-
croscopic discrimination between B-cell/myeloma fusions, other hybrids and unfused
myeloma cells was not possible. It may be approx. 10−4 comparable to standard PEG
fusion protocols (LANE, 1985).
Instead of the labour intensive limiting dilution steps hybridoma cloning was done
by FACS. This cloning strategy has several advantages in comparison to the limiting
dilution procedure. It is a quick and easy method. Single cell clones are obtained
in only one sorting step which eliminates the risk of overgrowing of valuable clones
by others and secures the diversity of the hybridoma population. Additionally viable
cells from cultures containing only few viable cells can be cloned with high efficiency.
Already in 1978 PARKS et al. managed to save 1 viable cell out of a culture containing
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more than 3000 dead cells, which indicates that the single cell sorting is also a method
that does not cause additional stress to cells. Therefore FACS is an efficient tool for
antigen specific cloning of antibody producing hybridoma cells (PARKS et al., 1979).
The propagation of single cells is known to be very difficult. Layers of macrophage
feeder cells provide the conditions and support for the growth of single cells (PETERS
and BAUMGARTEN, 1990). To circumvent the elaborate application of feeder cells,
where killing of the cells by radioactivity is required before cultivation, optimisation
concerning fusion partner and culture medium had to be done for the single cell cul-
turing. As fusion partner Sp2/mIL-6 cells were chosen, which constitutively express
murine IL-6, an important growth factor for hybridoma cells (HARRIS et al., 1992). Fur-
thermore the medium had to be adjusted to the special requirements of the single hy-
bridoma cells. More cells survived when they were sorted into their original culture
supernatant supplemented with 50% (v/v) fresh HAT medium. Beside other growth
factors conditioned medium includes high amounts of IL-6 produced by the B-cells
fused to Sp2/mIL-6 themselves, which significantly enhances the survival of single
cells. Using this improvement growth rates of 30-40% could be achieved. The survival
rate might have been even higher, as the settings of the FACS machine guaranteed the
deposition of 0-1 cell per well and therefore probably not everywell was occupied with
a cell.
Using the improved protocols 394 and 340 (F. Kampmeier, diploma thesis, RWTH
Aachen, BioVII, 2005) hybridoma clones respectively could be established from differ-
ent sorting approaches after immunisation with lung cancer cell and pancreatitis tissue
lysate. This number was only limited by the available manpower. The propagation of
the cells in cell culture was very time consuming and more hybridoma clones could
not be handled. Automatisation of this work as well as the management of back-ups
is possible by standard robotics but this was not accessible during this work. Robotics
would enable the handling of thousands of clones and are required for the establish-
ment of a high throughput generation of monoclonal antibodies.
Tomaximise the number of antigen specific hybridoma clones a pre-selection proce-
dure should be established. For this purpose the hybridoma cells were incubated with
fluorescently labelled cell lysate and subsequent FACS analysis. By this fluorescently
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marked single cells were single cell sorted.
Figure 3.18 shows the plots of the FACS analysis of hybridoma incubated with la-
belled BSA. BSA should not bind specifically to the surface of hybridoma cells. The
EVOblue signal of the whole cell population is therefore regarded as background sig-
nal originating from unspecific sticking of BSA to cell surface components. As a sec-
ond control an established monoclonal hybridoma cell line (Bo9) specific for the al-
lergen Phl p Vb from common timothy grass pollen was incubated with fluorescently
labelled lung cancer cell lysate. The EVOblue signal was not increased in comparison
to the signal aroused by labelled BSA. Few cells show an increased EVOblue signal,
but it is important to note that apoptotic cells emit auto-fluorescence that is detected in
the same channel as the EVOblue signal. A different fluorescent dye could circumvent
this limitation. FACS analyses of polyclonal as well as monoclonal hybridoma cells
incubated with tissue lysate revealed strong unspecific binding of tissue components
to the cells. This is probably originating from binding of antibodies or signal transduc-
tion molecules present in the tissue, but not or only in smaller amount in cell lysate,
to their specific receptors available on the cell surface of hybridoma cells (data shown:
F. Kampmeier, diploma thesis). This unspecific binding of the polyclonal hybridoma
cells could dramatically reduced by pre-incubation of the lysate with Bo9 hybridoma
cells.
Nevertheless the sorting approaches showed the difficulty to discriminate between
unspecific and antibody mediated specific binding. Even specific binding would not
result in a clearly definable cell population. The fluorescent signal depends on the
amount of bound labelled antigen and on the size of the antigen. Large proteins can
bindmore dye molecules than small proteins, leading to an increase of the signal inten-
sity. Homogenous proteins solutions like BSA are defined proteins solutions enabling
a homogenous labelling in a certain molar ratio. This is not possible with a tissue or
cell lysate that contains a large variety of different proteins. The right amount of dye
necessary to label all proteins in the mixture without over-labelling them could only
be estimated roughly. Low abundant proteins can not mark a cell in the same range as
high abundant proteins and therefore can not lift the cell above the high background
signal. Although fluorescently labelled cell or tissue lysates are used in the micro array
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technology (ZHU and SNYDER, 2003) this is not comparable to the approach on whole
cells, as complex matrix, described here. Improvements could be reached by using sta-
ble GFP transfected myeloma cells (done by S.Vogel, RWTH Aachen) for B-cell fusion
leading to a significant and strong fluorescence of hybridoma cells.
These results emphasise the problematic of pre-selection with complex antigenmix-
tures. Again an effective and reproducible pre-fractionating step would solve these
problems by providing a less complex andmore defined antigen source and enable the
enrichment of low abundant proteins (STASYK and HUBER, 2004). For single antigens a
FACS based selection has been successfully demonstrated using the antigen coupled to
fluorescent beads (PARKS et al., 1979). Pre-fractionating would lead to a more defined
antigen mixture. A defined antigen mixture with enriched low abundant protein could
be coupled to beads, which should lead to a distinct signal in FACS without disturbing
background as shown by PARKS et al. (1979). Furthermore with such a mixture and
robotics an ELISA based screening of all hybridoma clones would be possible. In this
case all living hybridoma clones would be sorted according to their GFP fluorescence.
Growing clones could be screened for antibody production in a sandwich ELISA. Pro-
ducing clones could then be testet for antigen specific antibodies in ELISA using de-
fined proteins mixtures prepared by pre-fractionating by 2D-LC for example. Using
an automated approach with robotics would enable the testing of thousands of clones
and reproducibility in the composition of the antigen mixture would be guaranteed by
the 2D-LC.
Despite these difficulties, during the numerous sorting approaches multiple hun-
dred single cells with the strongest signals were sorted and the growth rate could be
increased from 0% up to 40%. To proof a successful enrichment of antigen specific hy-
bridoma clones all clones have to be analysed and statistical calculations have to be
performed in the future.
4.2.2.3 Monoclonal Antibody Production
In order to establish a process suitable for high throughput and automatisation time
and money consuming purification steps should be circumvented. Purification of
monoclonal antibodies requires optimisation concerning buffer, matrix and method
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for every antibody and therefore is not feasable for an industrial high throughput ap-
proach. Therefore affinity matrices on beads were used for the subsequent immuno-
precipitation assuring the isolation of antibodies from culture medium. This was sim-
plified by production of antibodies in FCS free medium (CD (C) medium). Previous
purification approaches using Protein G and Protein A matrices showed a strong co-
purification of bovine antibodies present in the FCS of the medium (data shown: F.
Kampmeier, diploma thesis). These polyclonal antibodies should not disturb the im-
munoprecipitation process, due to the variety of specificities, nevertheless binding
sites will be occupied by these antibodies and therefore reduce the amount of mono-
clonal antibodies subjected into the immunoprecipitation. The CD (C) medium itself
is a protein free medium (FIKE et al., 2001). In 15 µl of medium loaded onto a SDS-
PAGE and subsequently stained with Coomassie Blue no protein could be detected as
expected (data not shown). Full size antibodies could be produced in visible amounts
using this medium (estimated 25-75 µg/ml). Most clones showed sufficient produc-
tion rates. But production rate could be further optimised if subcloning would be per-
formed. Good growing and non producing cells may overgrow producing cells during
the cultivation period. But subcloning of multiple hundred clones is, even with FACS,
a time andmoney consuming procedure, which should only be performed for interest-
ing clones for large scale production of antibodies and was not performed during this
work due to manpower limitations.
Different affinity matrix beads were used during this work. Although the Protein A
and Protein G beads have a higher binding capacity the GAM beads are more suitable
for this approach. The binding of antibodies to Protein A or Protein G is dependent
of the isotype and in combination to this different buffer systems are required. This
would assume the determination of the isotype of the monoclonal antibody which is
not feasable in high throughput due to financial aspects. Further for automatisation a
set up is required suitable for all antibodies. The GAM beads seem to provide these
requirements, by binding all kinds of IgG antibodies and as shown above also IgM
antibodies.
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4.2.2.4 Immunoprecipitation and Antigen Identification
The antigens of 2 hybridoma clones (HFL1-1, HFL1-22) derived from mice immunised
with lung cancer cells could be determined. Additionally the antigens of 5 hybridoma
clones derived from the mouse immunised with pancreatitis lysate could be identi-
fied (done by F. Kampmeier). Two analysis approaches were performed, one using
direct MS analysis of the elution fraction and analysis of proteins bands separated by
intermediate SDS-PAGE. Both approaches delivered no homogenous good results. In
many cases the peptide amount after digestion of the elution fraction as well as af-
ter digestion of isolated bands was too low for MS analysis (personal communication
with M. Kuepper, RWTH Aachen). This emphasises the need for optimisation of the
protocol. In the need for protocols suitable for high throughput and automatisation
the efforts should be concentrated on the first and direct approach. This approach was
proven by the model systems H22-CD64 and Bo9-PV and by this approach the antigen
of 3 different hybridoma clones could be identified. Again pre-fractionating steps and
therefore more defined protein mixtures including low abundant proteins in enriched
amounts will be required. WEILER et al. (2003) used a comparable set up. With 50-500
ngmonoclonal antibody theymanaged to identify antigens present in the mixture with
1.5 pmol.
The antigen β-globin could be determined by both approaches. Two beta-globin
chains together with 2 alpha chains form the oxygen transport molecule haemoglobin.
Beta-globin consists of 146 amino acids with a molecular weight of 16.013 Dalton. Be-
cause of the strong vascularisation of cancerous tissue and the higher blood flow in
inflamed tissue, the amount of beta-globin and to the same extend alpha globin in the
samples is likely to be comparably high.
The second identified antigen, the pancreatic alpha amylase 2A, is of clinical rele-
vance. Alpha amylase 2A is an enzyme of the starch metabolism; it cleaves the α-
1-4 glycosidic bond between two glucose molecules in amylose and amylopectin. In
several studies increased level has been found in association with pancreatic disease
(IGNJATOVIC et al., 2000; IACOBUZIO-DONAHUE et al., 2003; LOGSDON et al., 2003; HU
et al., 2004; SHEN et al., 2004). Pancreatic alpha amylase is commonly used for the
diagnosis of acute pancreatitis where an up to three fold increase in concentration of
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the enzyme is observed in the serum.
The dedicator of cytokinesis protein 5 (DOCK5) found as one potential antigen of
the antibody HFL1-1 derived from a mouse immunised with HFL1 cells belongs to the
DOCK protein family and is of 804 amino acids in length. It is a potential guanine
nucleotide exchange factor (GEF) (STRAUSBERG et al., 2002). GEF proteins activate
some small GTPases by exchanging bound GDP for free GTP. The second potential
antigen is similar to eucaryotic translation initiation factor 4E nuclear import factor 1,
which is of 811 amino acids in length. An alignment of the sequences of both proteins
revealed 9 areas of overlapping sequences with identities higher than 50% (data not
shown). It is possible, that the HFL1-1 antibody binds to epitopes present on both
proteins. Epitope mapping or structure modelling could give a hint to that suggestion.
The antigen of the antibody HFL1-22 was identified to be similar to CG5882-PA,
replaced now by hypothetical protein LOC159686, including 872 amino acids. There
is no further information available concerning this protein. Nevertheless regions of
the protein show similarities to proteins including a myosin like domain. To follow
this hint, that this protein could be located to the cell membrane, molecular imaging
was successfully performed confirming the suggestion regarding the localisation of the
protein.
The identification of unknown antigens via immunoprecipitation with subsequent
MS analysis was reached in two ways during this project, once by direct digestion
and proceeding of the eluted proteins after the capturing procedure. The second way
includes an intermedial SDS-PAGE of the eluted proteins after capturing and in gel
digest of specific protein bands. Independent of the method, optimisation of both pro-
tocols and MS analysis is required to assure reproducible good results.
4.2.3 Conclusion
The second aim of this thesis was to establish a process suitable for generation of an-
tibodies against the variety of proteins of the whole proteome and the identification
of the according antigen. While the first approach using the phage display technol-
ogy was limited by technical resources, the process could be successful established
using the hybridoma technique. Although antigens in general and even an antigen of
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clinical relevance (alpha 2A amylase) could be identified this approach can only lead
to success if a huge number of hybridoma cells is screened. This suggestions is em-
phasised by a related approach described by LAMPE et al. (2004). In this approach
30 mice were immunised with prostate carcinoma lysate resulting 25.000-50.000 hy-
bridoma clones. 0.05% were found to react specifically with prostate tissue, none was
found to be prostate carcinoma specific. The number of sorted cells could be decreased
by an effective screening procedure. But this is limited as well as the immunisation
by the complexity of the antigen mixture. An effective pre-selection could reduce this
problem.
Nevertheless the single cell sorting, culturing of single cells and the identification of
corresponding antigens could be established within the range of this project, although
optimisation of the immunoprecipitation and MS analysis is required. WEILER et al.
(2003) used a comparable set up. With 50-500 ng monoclonal antibody they reached
to identify antigens present in the mixture with 1.5 pmol. Differences in the sample
preparation prior to MS analysis could be the cause for the high sensitivity reached in
this approach.
An automatisation of the culturing and screening of the hybridoma clones could
lead to a successful production of antibodies against almost every protein of the pro-
teome, suitable for diagnosis chips of early stages of lung or pancreatic cancer. Addi-
tionally, interesting antibodies for a variety of different applications will be generated.
4.2.4 Outlook
The long term goal of the second project is on the one hand the generation of antibodies
specific for proteins present in lung or pancreatic cancer enabling the diagnosis of these
diseases in early stages of development via protein chips. On the other hand antibodies
are to be generated against as many proteins as possible of the human proteome. The
limitation seemed to be the complexity of the antigen mixture. Pre-fractionation steps
could solve this problem, for example by fractions of proteins of the same size, the
same pI or the same cell compartiment. Furthermore the 2-dimensional liquid chro-
matography (2D-LC) enables the comparatative studies of the proteome of different
cells, identifying proteins with an altered expression or modification between healthy
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and disease samples. Enrichment of these proteins enables directed immunisation and
screening for high affinity antibodies. The 2-dimensional liquid chromatography could
be used to isolate single proteins in a exact reproducable way. These proteins could on
the one hand be combined to defined protein mixtures of a few proteins used for im-
munisation of mice and on the other side they could be identified by directMS analysis.
Identification of specific hybridoma could be achieved by antigen ELISA with coated
single protein from 2D-LC. These steps (2D-LC, FACS, MS analysis, cell culture work,
ELISA) can completely be automised and are therefore suitable for high throughput.
Using the approach presented in this work, the identification of the antigen re-
quires strong optimisation. Using the intermediale SDS-PAGE is not suitable for high
throughput procedures. Therefore the direct procedure should be optimised regarding
sensitivity. The loss of protein could be reduced by direct application of the sample
to MS analysis. ZHUKOV et al., (2004) describe an interesting approach using the Bi-
acore3000, where the antigen is eluted from the Biacore and transferred directly onto
MALDI target followed by automated digestion and MS analysis.
The antibodies with identified antigens should be further characterised. MACHT
et al., (2003) showed a combination of epitope-excision of affinity-bound proteins with
a database search subsequent to MS analysis as suitable tool for the identification of
epitopes. Tests for cross reactivity can be performed if applications for the antibody
are considered.
Chapter 5
Summary
The aim of the first part of this thesis was to generate an antibody against Nonylphenol
for later use in biofilters for the elimination of NP from waste water. For this purpose
mice were immunised following different strategies. The immunisation according to
High Zone Tolerisation led to the best results regarding a nonylphenol specific anti-
body titre in the mouse serum. Successful fusion of the murine B-cells with myeloma
cells were performed followed by single cell sorting (FACS). Monoclonal clones could
be established and at least 4 stable cell lines showed specific binding to NP in ELISA.
One antibody was further tested in a ligand fishing approach with subsequent GCMS
analysis of the supernatant which proved the binding to NP.
The aim of the second part was the establishment of a procedure for the generation
of antibodies specific for proteins of lung cancer and pancreatic cancer, respectively,
and subsequent identification of these proteins. The approach was designed to pre-
pare the ground for the establishment of a high throughput setup for the proteome
wide production of monoclonal antibodies, focusing on the discovery of a compilation
of targets with potential diagnostic or therapeutic value. Mice were immunised with
whole cells, cell lysates as well as tissue lysates. The development of a specific anti-
body titre could be proven by ELISA for all antigens. Mouse spleen cells were fused
with Sp2/mIL-6 myeloma cells. In the scope of this project the single cell sorting of hy-
bridoma cells could be established followed by the successful culturing of single cells
resulting in growth rate of up to 40%. By this 394 and 340 (F. Kampmeier) antibody
producing clones were obtained. Only a part of these clones could be analysed due to
time and manpower limitations. For antibody production a protein free medium was
used. In combination with affinity matrix beads the need of time and money consum-
ing purification steps is circumvented. The antibodies were used for immunoprecipi-
tation experiments and subsequent identification of the antigens by MS analysis. The
functionality of this approach could be proven by model systems using antibodies of
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known specificity with lysate spiked with the appropriate antigen. Five new antigens
could be identified by this method. The presented results confirm the suitability of
the approach for the production and characterisation of antibodies against a variety of
targets.
Chapter 6
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Chapter 7
Adendum
Abbrevations
2DE Two-dimensional-gel electrophoresis
2D-PAGE Two-dimensional polyacrylamide gel electrophoresis
A adenine (DNA-Base)
A ampere
AA acrylamide
AA aminoacid
Ag antigen
AGEESA Aachener Graduate College for the Elimination of Endocrine Disrupting
Substances fromWastewater
Ab antibody
AP alcalic phosphatase
AP alkylphenols
APE alkylphenolspolyethoxylates
Bp basepair
C cytosine (DNA-Base)
◦C degree celsius
cBSA cationised bovine serum albumin
CDR complementary determining region
CH constant region of the heavy chain
CL constant region of the light chain
CT computer tomography
dNTP Desoxynukleosid-Triphosphat
DTT dithiothreitol
E extinction
E.coli Escherichia coli
EDC 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
ELISA Enzyme Linked Immunosorbent Assay
ERE estrogen responsive element
Fab fragment antigen binding
FACS fluorescent-activated cell sorter
Fc fragment crystalisable
fg femtogram
FITC Fluoresceinisothiocyanat
fmol femtomol
FR framework (conserved region in the variable domains of antibodies)
Fv fragment variable
g acceleration due to gravity (9,81 ms−2)
g gram
G guanine (DNA-Base)
GAM goat anti mouse
h hour
HRP horse radish peroxidase
IgM, IgG, IgA, IgE, IgD immunoglobuline of the isotypes M, G, A, E und D
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kDa kilodalton
kV kilovolt
λ Lambda
M molar
mA milliampere
mAb monoclonal antibody
µg microgram
mg milligram
MHC-Complex major histocompatibiliy
µl microliter
ml milliliter
min minute
mM millimolar
mm millimeter
MOPS 3-(N-Morholino-)Propansulfonsäure
MS mass spectrometry
ng nanogram
nm nanometer
ng nanogram
NP nonylphenol
NSCLC non-small cell lunger cancer
ω Ohm
OD optical density
ori origin of replication
pIII / pVIII coat proteins of filamentous phages
p.a. pro analysi
PAA polyacrylamide
PAGE PAA-gelelectrophoresis
PBS phosphate buffered saline
PBS-T PBS + 0,05% (v/v) Tween-20
PCR Polymerase Chain Reaction
pg picogram
BSA bovine serum albumin
RT room temperature
SAM sheep anti mouse
SCLC small cell lung cancer
sec second
scFv single chain fragment of the variable region
SDS natriumdodecylsulfat
T Thymine (DNA-Base)
Taq Thermus aquaticus
TMB 3,3’,5,5’ Tetramethylbenzidin
TP Anlagerungstemperatur eines Oligonukleotids
Tris Tris-(hydroxymethyl)-aminomethan
U Unit
on over night
rpm rounds per minute
UV ultraviolett
V volt
v/v volume per volume
VH variable region of the heavy chain
VL variable region of the light chain
Vol volume
W watt
w/v weight per volume
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One Letter Code for Aminoacids
A alanine
C cysteine
D aspartate
E glutamate
F phenylalanine
G glycine
H histidine
I isoleucine
K lysine
L leucine
M methionine
N asparagine
P proline
Q alutamine
R arginine
S serine
T threonine
V valine
W tryptophane
Y tyrosine
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